var title_f10_35_10800="AV fistula after renal bx Angio";
var content_f10_35_10800=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F59858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F59858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Renal AV fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arteriovenous fistula following biopsy of a transplanted kidney. Following injection of contrast material into the right common iliac artery (long arrow), there is prompt filling of the iliac vein (short arrow) with poor perfusion of the transplanted kidney.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_35_10800=[""].join("\n");
var outline_f10_35_10800=null;
var title_f10_35_10801="Lercanidipine: International drug information";
var content_f10_35_10801=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"23\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lercanidipine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4304147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cardiovasc (IT);",
"     </li>",
"     <li>",
"      Carmen (DE);",
"     </li>",
"     <li>",
"      Corifeo (DE);",
"     </li>",
"     <li>",
"      Lercadip (ES, IT);",
"     </li>",
"     <li>",
"      Lercan (FR);",
"     </li>",
"     <li>",
"      Lerdip (NL);",
"     </li>",
"     <li>",
"      Lerzam (ES);",
"     </li>",
"     <li>",
"      Zanedip (IT);",
"     </li>",
"     <li>",
"      Zanidip (AT, BE, DK, ES, FR, GB, NL, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Lercanidipine Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mild to moderate hypertension",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Initial: 10 mg once daily; may increase, if necessary, after at least 2 weeks to 20 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 10 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10405 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-31BEBB80C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_35_10801=[""].join("\n");
var outline_f10_35_10801=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4304147\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979272\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979274\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979301\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979273\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821110\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979276\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10405\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10405|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_35_10802="Bonfils fiberoptic stylts";
var content_f10_35_10802=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bonfils fiberoptic stylets",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Image courtesy of KARL STORZ Endoskope, Germany.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_35_10802=[""].join("\n");
var outline_f10_35_10802=null;
var title_f10_35_10803="Omental flap for rectal anast";
var content_f10_35_10803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Omental flap for rectal anastomosis during pelvic exenteration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_35_10803=[""].join("\n");
var outline_f10_35_10803=null;
var title_f10_35_10804="Normal female anat detail";
var content_f10_35_10804=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Normal female reproductive anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 463px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_35_10804=[""].join("\n");
var outline_f10_35_10804=null;
var title_f10_35_10805="Controversies in control measures to prevent surgical site infection";
var content_f10_35_10805=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Controversies in control measures to prevent surgical site infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/35/10805/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/35/10805/contributors\">",
"     Deverick J Anderson, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/35/10805/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/35/10805/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/35/10805/contributors\">",
"     Anthony Harris, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/35/10805/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/35/10805/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/35/10805/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical wound infections are the second most common nosocomial infection. Although usually localized to the incision site, surgical wound infections can also extend into adjacent deeper structures; thus, the term surgical wound infection has now been replaced with the more suitable name, surgical site infection (SSI).",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention (CDC) has developed criteria for defining SSIs, which have become the national standard and are widely used by surveillance and surgical personnel. These criteria define SSIs as infections related to the operative procedure that occur at or near the surgical incision (incisional or",
"    <span class=\"nowrap\">",
"     organ/space)",
"    </span>",
"    within 30 days of an operative procedure or within one year if an implant is left in place. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36406?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and pathogenesis of and risk factors for surgical site infection\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Controversies in control measures to reduce SSI rates will be reviewed here. Standard control measures to reduce SSI rates, including antimicrobial prophylaxis, and the definition, epidemiology, risk factors, and pathogenesis of SSIs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36406?source=see_link\">",
"     \"Epidemiology and pathogenesis of and risk factors for surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUPPLEMENTAL PERIOPERATIVE OXYGEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perfusion and oxygenation of the subcutaneous tissues contribute to the prevention of SSI. Previous studies have suggested that subcutaneous wound oxygen tension inversely correlates with the development of wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/1\">",
"     1",
"    </a>",
"    ]. Three clinical trials evaluated the benefit of the administration of 80 percent oxygen (FiO2 = 80 percent) during the course of abdominal surgery with different results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter, randomized European trial in 500 patients evaluated the benefits of supplemental oxygen during and immediately after elective colorectal surgery in enhancing tissue oxygen levels to create an environment less hospitable to microorganisms [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/2\">",
"       2",
"      </a>",
"      ]. Patients received prophylactic intravenous antibiotics, a standard bowel preparation without intraluminal antibiotics, vigorous postoperative hydration for 48 hours, and were randomly assigned to receive 80 or 20 percent FiO2. The group of patients that received 80 percent FiO2 had a significantly lower rate of SSI than the control group that received 30 percent FiO2 (5 versus 11 percent). However, the results should be interpreted with some caution since infection rate in the control group was quite high for elective colorectal procedures, and this group had a significantly higher risk score for infection using two different methods including the NNIS system and patient preoperative data.",
"     </li>",
"     <li>",
"      A second trial in New York City compared 80 percent FiO2 with 35 percent in 165 patients undergoing a variety of elective abdominal procedures including colectomy, low anterior resection, gastrectomy, pancreaticoduodenectomy, exploratory laparotomy, and gynecologic debulking procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/3\">",
"       3",
"      </a>",
"      ]. Patients receiving high oxygen supplementation had a significantly higher incidence of SSI compared with those receiving lower oxygen concentrations (25 versus 11.3 percent) and a significantly longer hospital stay following surgery (13.3 versus 6 days). A high FiO2 was a significant factor in the development of SSI in a multivariate analysis.",
"     </li>",
"     <li>",
"      A third study randomly assigned 300 adults undergoing planned open colorectal surgery in Spain to receive 30 or 80 percent supplemental oxygen intraoperatively and for six hours postoperatively [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/4\">",
"       4",
"      </a>",
"      ]. During the first 15 postoperative days, significantly fewer patients in the 80 percent oxygen group developed infections (15 versus 24 percent in the 30 percent oxygen group).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reasons for the discrepancy in these studies are not known, although the study that did not show a benefit was the smallest of the studies. Further trials would be required before any recommendation to use high oxygen supplementation routinely could be made, although the low cost and low risk of high supplemental oxygen therapy and the strong scientific rationale make this intervention attractive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SUBCUTICULAR SUTURING VERSUS SKIN STAPLING TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcuticular sutures and staples are commonly used for closure of sternal and leg incisions in patients undergoing CABG. One study demonstrated that staple use for skin closure was an independent risk factor for deep sternal site infection (OR, 4.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/5\">",
"     5",
"    </a>",
"    ]. Two randomized controlled trials have compared these two techniques and the risk of SSI.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial involving 80 patients was undertaken to determine the best technique for reducing the postoperative leg wound infection rate [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/6\">",
"       6",
"      </a>",
"      ]. Although the major infection rate was reduced from 13 to 3 percent during the study period, each closure method was equally effective.",
"     </li>",
"     <li>",
"      Another study prospectively randomized 162 patients undergoing CABG to have their sternal and leg incisions closed with either a subcuticular suture technique or with a skin clip [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/7\">",
"       7",
"      </a>",
"      ]. The investigators concluded that subcuticular suturing was preferable based upon increased costs for clips and a greater sternal wound infection rate. There were also trends toward increased rates of in-hospital sternal and leg incision inflammation and a greater rate of mediastinitis at follow-up assessment when the wounds were closed with skin clips.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANEMIA AND LEUKOCYTE-DEPLETED RED BLOOD CELL TRANSFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative anemia and perioperative anemia are significant risk factors for SSI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study involving 6301 noncardiac surgical patients used multiple logistic regression analysis to document that low preoperative hematocrit, low postoperative hematocrit, and increased blood transfusion rates were associated with increased mortality, increased postoperative pneumonia, and increased hospital length of stay [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another author studied the relationship between perioperative blood transfusion and postoperative infectious complications in 343 consecutive patients undergoing surgery for colorectal cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/10\">",
"       10",
"      </a>",
"      ]. Thirty-three of the 134 patients (25 percent) who received transfusions developed infectious complications compared with nine of the 209 patients (4 percent) who did not receive blood.",
"     </li>",
"     <li>",
"      A similar study investigated 1,349 patients undergoing colorectal surgery in 11 centers across Canada [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/11\">",
"       11",
"      </a>",
"      ]. A significantly higher frequency of wound infections and intraabdominal sepsis occurred in the patients who were transfused (26 versus 14 percent). A significant dose-response relationship between transfusion and infection rate was also demonstrated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some authors have suggested that leukocytes in transfused blood are associated with several posttransfusion immunomodulatory effects that may predispose to SSIs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/12\">",
"     12",
"    </a>",
"    ]. Several studies have investigated whether filtering leukocytes from blood prior to transfusion might reduce the risk of postoperative infection associated with blood transfusion. One such study compared buffy-coat poor and filtered leukocyte-depleted red cells in patients undergoing elective colorectal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients were randomized to receive one or the other type of blood product, but not all assigned patients required transfusion. The 142 patients randomized to and transfused with buffy-coat-poor blood had a significantly higher frequency of wound infections and intraabdominal abscesses than the 118 randomized to and receiving leukocyte-depleted blood (12 versus 0 and 5 versus 0 percent, respectively). However, there was no difference in mortality among the groups and patients who did not require blood transfusion had a lower infection rate than those who received either blood product. A similar prospective randomized trial in colorectal patients demonstrated a reduction in the frequency of postoperative infection, the length of hospital stay, and the total hospital charges for patients needing blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/14\">",
"     14",
"    </a>",
"    ]. Smaller studies have not reproduced these results in colorectal or cardiac surgery, and larger, randomized, well-controlled trials are needed to demonstrate the benefit of leukocyte-depleted red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LAMINAR FLOW IN ORTHOPEDIC SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of SSI is increased when foreign material (eg, sutures, prostheses, indwelling device, or implant) is placed into a patient. CNS and, to a lesser degree, S. aureus have been shown experimentally to produce a glycocalyx or \"slime\" in the presence of foreign material that can develop into a biofilm. The biofilm adheres to the foreign substance, shielding the infecting bacteria from phagocytosis and immune-related destruction. This slime layer also inhibits the action of antimicrobial agents [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When a foreign body is present, the minimum inoculum of organisms capable of producing a SSI is markedly lower. As an example, studies have demonstrated the pathogenic potential of a single bacterium to produce a SSI following the placement of a foreign body [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the risk of SSI in operations involving prosthesis or implants is higher, the air in the operating room should be as free of microorganisms as possible. The level of organisms in the air can be reduced through dilution by high-volume exchanges with clean filtered air and the introduction of outside air. In addition to high volume exchanges, laminar flow is designed to move particle-free air (\"ultraclean air\") over the aseptic operating field at a uniform velocity (vertically or horizontally).",
"   </p>",
"   <p>",
"    The use of ultra-clean air or laminar flow ventilation systems has been extensively studied in patients undergoing insertion of orthopedic devices. These prospective and controlled studies demonstrated a decrease in rates of SSI in total hip and knee prosthesis procedures when laminar airflow technology was used [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In one study of 8000 total hip and knee procedures, operations performed in ultra-clean air resulted in fewer deep infections compared to a conventional operating room (0.6 versus 1.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, even under laminar flow, bacteria can be predictably isolated from wound surfaces at the close of the operation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, the value and cost-effectiveness of laminar airflow is questionable when surgery occurs in modern facilities that have high rates of air exchange and use antimicrobial prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. In a case control study of 26,505 patients undergoing total hip or knee replacement with an infection rate of 1.8 percent, laminar flow ventilation was not a significant factor in reducing infections in a univariate analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10805/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/1\">",
"      Hopf HW, Hunt TK, West JM, et al. Wound tissue oxygen tension predicts the risk of wound infection in surgical patients. Arch Surg 1997; 132:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/2\">",
"      Greif R, Ak&ccedil;a O, Horn EP, et al. Supplemental perioperative oxygen to reduce the incidence of surgical-wound infection. N Engl J Med 2000; 342:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/3\">",
"      Pryor KO, Fahey TJ 3rd, Lien CA, Goldstein PA. Surgical site infection and the routine use of perioperative hyperoxia in a general surgical population: a randomized controlled trial. JAMA 2004; 291:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/4\">",
"      Belda FJ, Aguilera L, Garc&iacute;a de la Asunci&oacute;n J, et al. Supplemental perioperative oxygen and the risk of surgical wound infection: a randomized controlled trial. JAMA 2005; 294:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/5\">",
"      Trick WE, Scheckler WE, Tokars JI, et al. Modifiable risk factors associated with deep sternal site infection after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2000; 119:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/6\">",
"      Mullen JC, Bentley MJ, Mong K, et al. Reduction of leg wound infections following coronary artery bypass surgery. Can J Cardiol 1999; 15:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/7\">",
"      Chughtai T, Chen LQ, Salasidis G, et al. Clips versus suture technique: is there a difference? Can J Cardiol 2000; 16:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/8\">",
"      Malone DL, Genuit T, Tracy JK, et al. Surgical site infections: reanalysis of risk factors. J Surg Res 2002; 103:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/9\">",
"      Dunne JR, Malone D, Tracy JK, et al. Perioperative anemia: an independent risk factor for infection, mortality, and resource utilization in surgery. J Surg Res 2002; 102:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/10\">",
"      Tartter PI. Blood transfusion and infectious complications following colorectal cancer surgery. Br J Surg 1988; 75:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/11\">",
"      Chang H, Hall GA, Geerts WH, et al. Allogeneic red blood cell transfusion is an independent risk factor for the development of postoperative bacterial infection. Vox Sang 2000; 78:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/12\">",
"      Tartter PI, Mohandas K, Azar P, et al. Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery. Am J Surg 1998; 176:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/13\">",
"      Jensen LS, Kissmeyer-Nielsen P, Wolff B, Qvist N. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996; 348:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/14\">",
"      Jensen LS, Grunnet N, Hanberg-S&oslash;rensen F, J&oslash;rgensen J. Cost-effectiveness of blood transfusion and white cell reduction in elective colorectal surgery. Transfusion 1995; 35:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/15\">",
"      Titlestad IL, Ebbesen LS, Ainsworth AP, et al. Leukocyte-depletion of blood components does not significantly reduce the risk of infectious complications. Results of a double-blinded, randomized study. Int J Colorectal Dis 2001; 16:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/16\">",
"      van de Watering LM, Hermans J, Houbiers JG, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998; 97:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/17\">",
"      Zimmerli W, Waldvogel FA, Vaudaux P, Nydegger UE. Pathogenesis of foreign body infection: description and characteristics of an animal model. J Infect Dis 1982; 146:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/18\">",
"      Dougherty SH, Simmons RL. Endogenous factors contributing to prosthetic device infections. Infect Dis Clin North Am 1989; 3:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/19\">",
"      Kaiser AB, Kernodle DS, Parker RA. Low-inoculum model of surgical wound infection. J Infect Dis 1992; 166:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/20\">",
"      Lidwell OM, Lowbury EJ, Whyte W, et al. Effect of ultraclean air in operating rooms on deep sepsis in the joint after total hip or knee replacement: a randomised study. Br Med J (Clin Res Ed) 1982; 285:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/21\">",
"      Fitzgerald RH Jr. Total hip arthroplasty sepsis. Prevention and diagnosis. Orthop Clin North Am 1992; 23:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/22\">",
"      Aglietti P, Salvati EA, Wilson PD Jr, Kutner LJ. Effect of a surgical horizontal unidirectional filtered air flow unit on wound bacterial contamination and wound healing. Clin Orthop Relat Res 1974; :99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/23\">",
"      Marotte JH, Lord GA, Blanchard JP, et al. Infection rate in total hip arthroplasty as a function of air cleanliness and antibiotic prophylaxis. 10-year experience with 2,384 cementless Lord madreporic prostheses. J Arthroplasty 1987; 2:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/24\">",
"      Lidwell OM. Clean air at operation and subsequent sepsis in the joint. Clin Orthop Relat Res 1986; :91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/25\">",
"      Persson U, Montgomery F, Carlsson A, et al. How far does prophylaxis against infection in total joint replacement offset its cost? Br Med J (Clin Res Ed) 1988; 296:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10805/abstract/26\">",
"      Berbari EF, Hanssen AD, Duffy MC, et al. Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis 1998; 27:1247.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4044 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-42B5A9483A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_35_10805=[""].join("\n");
var outline_f10_35_10805=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUPPLEMENTAL PERIOPERATIVE OXYGEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SUBCUTICULAR SUTURING VERSUS SKIN STAPLING TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANEMIA AND LEUKOCYTE-DEPLETED RED BLOOD CELL TRANSFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LAMINAR FLOW IN ORTHOPEDIC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36406?source=related_link\">",
"      Epidemiology and pathogenesis of and risk factors for surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_35_10806="Gleason grading prost adenoCA";
var content_f10_35_10806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gleason grading of prostate cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 419px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Simplified drawing of the histologic patterns of prostatic adenocarcinoma, emphasizing the degree of glandular differentiation. Five distinct patterns or grades are recognized on a scale from 1 to 5 (from well differentiated to poorly differentiated).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wheeler TM. Anatomy of the prostate and the pathology of prostate cancer. In: Genitourinary Oncology, Vogelzang N, Scardino PT, Shipley WU, Coffey DS (eds), Lippincott Williams &amp; Wilkins, Philadelphia 2000. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_35_10806=[""].join("\n");
var outline_f10_35_10806=null;
var title_f10_35_10807="Quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine: Drug information";
var content_f10_35_10807=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/2/16417?source=see_link\">",
"    see \"Quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/3/36918?source=see_link\">",
"    see \"Quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Menactra&reg;;",
"     </li>",
"     <li>",
"      Menveo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12592734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Menactra&reg;;",
"     </li>",
"     <li>",
"      Menveo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F192585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Inactivated (Bacterial)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F192573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Immunization:",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Menactra&reg;, Menveo&reg;: Adults &le;55 years: 0.5 mL/dose given as single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      ACIP recommendations:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Adults &le;55 years with persistent complement component deficiency; functional or anatomic asplenia or HIV infection: Two doses, 2 months apart. A booster dose should be given every 5 years if still at risk for meningococcal disease (CDC, 60[3], 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Adults &le;55 years with prolonged increased risk of exposure: One dose. A booster dose should be given every 5 years if still at risk for meningococcal disease (CDC, 60[3], 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     College students: Persons &le;21 years of age should have documentation of vaccination &le;5 years prior to enrollment. If the primary dose was given at &lt;16 years of age, a booster dose should be given any time after the 16th birthday and prior to college enrollment. The minimum interval between doses is 8 weeks (CDC, 60[3], 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F192581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/3/36918?source=see_link\">",
"      see \"Quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Immunization:",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Menactra&reg;: Children 9-23 months: 0.5 mL/dose given as a 2-dose series, 3 months apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Menactra&reg;, Menveo&reg;: Children &ge;2 years: 0.5 mL/dose given as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      ACIP recommendations: Routine/primary vaccination:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Children 11-18 years of age: Routine vaccination: One dose at 11 or 12 years of age with a one-time booster dose (see 'Booster dose' section). Children in this age group receiving routine vaccination and who are also HIV positive should initially receive two doses, 2 months apart, and a booster dose as recommended, based on age at primary dose (see 'Booster dose' section) (CDC, 60[3], 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Children 9-23 months of age at high risk for invasive meningococcal disease (except those with functional or anatomic asplenia): Two doses, 3 months apart. A booster dose should be given as recommended if still at risk for meningococcal disease (see 'Booster dose' section) (CDC, 60[40], 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Children &ge;2 years with persistent complement component deficiency, or functional or anatomic asplenia or HIV infection: Two doses, 2 months apart. A booster dose should be given as recommended if still at risk for meningococcal disease (see 'Booster dose' section) (CDC, 60[3], 2011; CDC, 60[40], 2011). Children at high risk for invasive meningococcal disease with functional or anatomic asplenia should receive their first dose at 2 years of age and &ge;4 weeks after completion of the PCV13 vaccine series (CDC, 60[40], 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Children &ge;2 years with prolonged increased risk of exposure: One dose. If still at risk for meningococcal disease, a booster dose should be given as recommended based  on the age at first dose (see 'Booster dose' section) (CDC, 60[3], 2011; VFC Resolution No. 6/11-1).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     College students: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      ACIP recommendations: Booster dose:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Booster dose following routine vaccination: One booster dose should be given based on age at primary vaccination: If initial dose was at 11 or 12 years of age, a one-time booster dose should be given at age 16. If primary dose was given at age 13-15 years, a one-time booster dose should be given at 16-18 years of age. If primary dose was given &ge;16 years of age, no booster dose is needed (CDC, 60[3], 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Booster dose for all other indications in patients with continued risk:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     If first dose received at 9-23 months of age: Repeat dose 3 years after primary vaccination, and every 5 years thereafter if the person remains at increased risk (CDC, 60[40], 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     If first dose received at 2-6 years of age: Repeat dose 3 years after primary vaccination, and every 5 years thereafter if the person remains at increased risk (CDC, 2009; CDC, 60[3], 2011; CDC, 60[40], 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     If first dose received at &ge;7 years of age: Repeat dose 5 years after primary vaccination, and every 5 years thereafter if the person remains at increased risk (CDC, 2009; CDC, 60[3], 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16317901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16317902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F192561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Menactra&reg;: 4 mcg each of polysaccharide antigen groups A, C, Y, and W-135 [bound to diphtheria toxoid 48 mcg] per 0.5 mL [MCV4 or MenACWY-D]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Menveo&reg;: MenA oligosaccharide 10 mcg, MenC oligosaccharide 5 mcg, MenY oligosaccharide 5 mcg, and MenW-135 oligosaccharide 5 mcg [bound to CRM",
"     <sub>",
"      197",
"     </sub>",
"     protein 32.7-64.1 mcg] per 0.5 mL (0.5 mL) [MenACWY-CRM; supplied in two vials, one containing MenA powder and one containing MenCYW-135 liquid]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F192551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F192563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by I.M. route, preferably into the upper deltoid region. Do not administer via I.V., SubQ or I.D. route. For patients at risk of hemorrhage, the ACIP recommends &ldquo;it should be administered intramuscularly if, in the opinion of a physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient or family should be instructed concerning the risk of hematoma from the injection.&rdquo; Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (CDC, 60[2], 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     For I.M. administration only. Based on limited data, inadvertent SubQ administration provides a lower serologic response, however, the response is still considered to be protective. If inadvertently administered by the SubQ route, revaccination is not necessary.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC, 60[2], 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F192562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Provide active immunization of children and adults against invasive meningococcal disease caused by",
"     <i>",
"      N. meningitidis",
"     </i>",
"     serogroups A, C, Y, and W-135.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      The Advisory Committee on Immunization Practices (ACIP):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     ACIP recommends routine vaccination of all persons at age 11 or 12 years of age, followed by a booster at age 16 years of age (CDC, 60[3], 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     The ACIP also recommends vaccination for:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Children 9 through 23 months of age at increased risk for meningococcal disease (CDC, 60[40], 2011). Children at increased risk include:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     - Children traveling to or who reside in countries where",
"     <i>",
"      N. meningitidis",
"     </i>",
"     is hyperendemic or epidemic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     - Children with persistent complement component deficiencies (eg, C5-C9, properdin, factor H, or factor D)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Persons 2 through 55 years of age at increased risk for meningococcal disease (CDC, 60[3], 2011). Meningococcal conjugate vaccine (MCV4) is preferred for persons aged 2-55 years; meningococcal polysaccharide vaccine (MPSV4) is preferred in adults &ge;56 years of age (CDC, 2005). Persons at increased risk include:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     - Previously unvaccinated college freshmen living in dormitories",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     - Microbiologists routinely exposed to isolates of",
"     <i>",
"      N. meningitidis",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     - Military recruits",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     - Persons traveling to or who reside in countries where",
"     <i>",
"      N. meningitidis",
"     </i>",
"     is hyperendemic or epidemic, particularly if contact with local population will be prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     - Persons with persistent complement component deficiencies (eg, C5-C9, properdin, factor H, or factor D)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     - Persons with anatomic or functional asplenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Use is also recommended during meningococcal outbreaks caused by vaccine preventable serogroups (all recommended age groups) (CDC, 2005; CDC, 60[40], 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      The Canadian National Advisory Committee on Immunization (NACI):",
"     </b>",
"     NACI recommends a routine vaccination at ~12 years of age but no booster unless at a continued high risk of exposure. Either quadrivalent vaccine may be used; NACI does not have a preference.  NACI recommends use of Menveo&reg; (unlabeled use) for high risk persons 2 months to 2 years of age if vaccination with a quadrivalent vaccine is needed; may also be considered for use in persons &ge;56 years of age  (NACI, 39[1], 2013).  Additional recommendations may be found at  www.phac-aspc.gc.ca/publicat/ccdr-rmtc/13vol39/acs-dcc-1/index-eng.php",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3343086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issue:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Menactra&reg; (MCV4) should be administered by intramuscular (I.M.) injection only. Inadvertent subcutaneous (SubQ) administration has been reported; possibly due to confusion of this product with Menomune&reg; (MPSV4), also a meningococcal polysaccharide vaccine, which is administered by the SubQ route.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F192583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Actual percentages may vary by product and age group:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Crying (abnormal), drowsiness, fatigue, fever, headache, irritability, malaise, sleepiness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site: Erythema, induration, pain, redness, swelling, tenderness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Eating changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Acute disseminated encephalomyelitis, ALT increased, anaphylactic reactions, anaphylactoid reactions, balance disorder, bone pain, breathing difficulties, dizziness,  ear pain, eyelid ptosis, facial palsy, facial paresis,  Guillain-Barr&eacute; syndrome, hearing impaired, hypersensitivity, hypotension, injection site reactions (cellulitis, inflammation, pruritus), oropharyngeal pain, paresthesia, pruritus, seizure, skin exfoliation, syncope, tonic convulsion, transverse myelitis, upper airway swelling, urticaria, vasovagal syncope, vertigo, vestibular disorder, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F192565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to other meningococcal-containing vaccines or any component of the formulation including diphtheria toxoid or CRM",
"     <sub>",
"      197",
"     </sub>",
"     (a diphtheria toxin carrier protein)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F192554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Guillain-Barr&eacute; syndrome (GBS): Risk of developing GBS may be increased following vaccination in  persons previously diagnosed with GBS. The risk of developing GBS was evaluated in a study of healthcare claims of persons 11-18 years of age (n= ~9,600,000; 15% were vaccinated with Menactra&reg;); 72 cases of GBS were confirmed and none received the vaccine within 42 days prior to symptoms; 129 reported cases of GBS could not be confirmed or excluded. Data not currently available to assess possible risk of GBS following use of Menveo&reg;.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute illness: May consider deferring administration in patients with moderate or severe acute illness (with or without fever); may administer to patients with mild acute illness (with or without fever).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Meningococcal infections: Not to be used to treat meningococcal infections or to provide immunity against",
"     <i>",
"      N. meningitidis",
"     </i>",
"     serogroup B or diphtheria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines:  In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence: Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC 60[2], 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F192557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F192559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/C (manufacturer dependent) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F192568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with Menactra&reg; (therefore classified as pregnancy category C). An isolated teratogenic effect was observed in an animal developmental toxicity study; not necessarily vaccine related. Carcinogenic or mutagenic studies have not been performed. Patients should contact the Sanofi Pasteur Inc vaccine registry at 1-800-822-2463 if they are pregnant or become aware they were pregnant at the time of Menactra&reg; vaccination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Adverse events were not observed in animal reproduction studies conducted with Menveo&reg; (therefore classified as pregnancy category B). Patients should contact the Novartis Vaccines and Diagnostics Inc. pregnancy registry at 1-877-311-8972 if they are pregnant or become aware they were pregnant at the time of Menveo&reg; vaccination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Limited information is available following inadvertent use of meningococcal diphtheria conjugate vaccine during pregnancy; safety and effectiveness have not been established. Inactivated bacterial vaccines have not been shown to cause increased risks to the fetus (CDC, 60[2], 2011).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F192576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12602947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inactivated vaccines do not affect the safety of breast-feeding for the mother or the infant (CDC, 60[2], 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6870423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F192553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induces immunity against meningococcal disease via the formation of bactericidal antibodies directed toward the polysaccharide capsular components of",
"     <i>",
"      Neisseria meningitidis",
"     </i>",
"     serogroups A, C, Y and W-135.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC), &ldquo;Report from the Advisory Committee on Immunization Practices (ACIP): Decision Not to Recommend Routine Vaccination of All Children Aged 2-10 Years With Quadrivalent Meningococcal Conjugate Vaccine (MCV4),&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      ,  2008, 57(17):462-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/35/10807/abstract-text/18451758/pubmed\" id=\"18451758\" target=\"_blank\">",
"        18451758",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Br&ouml;ker M, Dull PM, Rappuoli R, et al, &ldquo;Chemistry of a New Investigational Quadrivalent Meningococcal Conjugate Vaccine That is Immunogenic at All Ages,&rdquo;",
"      <i>",
"       Vaccine",
"      </i>",
"      , 2009, 27(41):5574-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/35/10807/abstract-text/19619500/pubmed\" id=\"19619500\" target=\"_blank\">",
"        19619500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian National Advisory Committee on Immunization (NACI), Advisory Committee Statement, \"Update on the Use of Quadrivalent Conjugate Meningococcal Vaccines,\"",
"      <i>",
"       CCDR",
"      </i>",
"      , 2013, 39(1). Available at file://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/13vol39/acs-dcc-1/index-eng.php",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Inadvertent Misadministration of Meningococcal Conjugate Vaccine -- United States, June-August 2005,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2006, 55(37):1016-7. Available at file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5537a2.htm.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/35/10807/abstract-text/16988640/pubmed\" id=\"16988640\" target=\"_blank\">",
"        16988640",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Prevention and Control of Meningococcal Disease Recommendations of the Advisory Committee on Immunization Practices (ACIP).",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 54(RR-7):1-21. Available at file://www.cdc.gov/mmwr/pdf/rr/rr5407.pdf.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Recommendation of the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(40):1391-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/35/10807/abstract-text/21993344/pubmed\" id=\"21993344\" target=\"_blank\">",
"        21993344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/35/10807/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Syncope After Vaccination -- United States, January 2005-July 2007,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/35/10807/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Updated Recommendations for Use of Meningococcal Conjugate Vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      . 2011, 60(3):72-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/35/10807/abstract-text/21270745/pubmed\" id=\"21270745\" target=\"_blank\">",
"        21270745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Updated Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Revaccination of Persons at Prolonged Increased Risk for Meningococcal Disease,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2009, 58(37);1042-43. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5837a4.htm?s_cid=mm5837a4_e\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5837a4.htm?s_cid=mm5837a4_e",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perrett KP, Snape MD, Ford KJ, et al, &ldquo;Immunogenicity and Immune Memory of a Nonadjuvanted Quadrivalent Meningococcal Glycoconjugate Vaccine in Infants,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2009, 28(3):186-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/35/10807/abstract-text/19209097/pubmed\" id=\"19209097\" target=\"_blank\">",
"        19209097",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/35/10807/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reisinger KS, Baxter R, Block SL, et al, &ldquo;Quadrivalent Meningococcal Vaccination of Adults: Phase III Comparison of an Investigational Conjugate Vaccine, MenACWY-CRM, with the Licensed Vaccine, Menactra,&rdquo;",
"      <i>",
"       Clin Vaccine Immunol",
"      </i>",
"      , 2009, 16(12):1810-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/35/10807/abstract-text/19812260/pubmed\" id=\"19812260\" target=\"_blank\">",
"        19812260",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/35/10807/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10140 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-BC8603A877-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_35_10807=[""].join("\n");
var outline_f10_35_10807=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192572\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12592734\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192585\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192573\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192581\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317901\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317902\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192561\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192551\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192563\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192562\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343086\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192583\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192565\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192554\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299661\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192557\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192559\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192568\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192576\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12602947\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6870423\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192553\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10140\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10140|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/2/16417?source=related_link\">",
"      Quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/3/36918?source=related_link\">",
"      Quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_35_10808="Intracranial epidural hematoma in children: Clinical features, evaluation, and management";
var content_f10_35_10808=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intracranial epidural hematoma in children: Clinical features, evaluation, and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/35/10808/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/35/10808/contributors\">",
"     Edward S Ahn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/35/10808/contributors\">",
"     Mark R Proctor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/35/10808/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/35/10808/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/35/10808/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/35/10808/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/35/10808/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidural hematoma (EDH), also known as extradural hematoma, is a hemorrhage into the space between the dura and the overlying calvarium. It is almost exclusively caused by trauma. The morbidity and mortality result from mass effect on the brain as the hematoma grows and strips the dura away from the skull. EDH in children is managed similarly to adults, but it requires special knowledge of location and clinical presentation. Prompt diagnosis is critical to the successful management of EDH.",
"   </p>",
"   <p>",
"    This topic discusses the clinical features, diagnosis, and management of EDH in children. Epidemiology, anatomy, and pathophysiology of EDH in children as well as EDH in adults are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11222?source=see_link\">",
"     \"Intracranial epidural hematoma in children: Epidemiology, anatomy and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19112?source=see_link\">",
"     \"Intracranial epidural hematoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid overview provides the clinical features, diagnostic evaluation, and emergent management for epidural hematomas in children (",
"    <a class=\"graphic graphic_table graphicRef69494 \" href=\"UTD.htm?15/28/15821\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical features that may suggest an increased risk of EDH include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High risk mechanism, such as fall from a significant height, any mechanism involving a motor vehicle, direct blow to the temporal region, inflicted injury, or unknown mechanism (which may represent inflicted injury)",
"     </li>",
"     <li>",
"      A lucid interval (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Lucid interval'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Headache, vomiting, seizure, confusion, lethargy, or loss of consciousness",
"     </li>",
"     <li>",
"      Preexisting bleeding disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any altered mental status associated with head injury in a child should raise suspicion for an epidural hematoma. This heightens the significance of a parental complaint that their infant or child is \"not acting right\". Physical findings vary by age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Neonates and infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;In neonates and infants with open fontanelles and sutures, clinical signs are nonspecific or may be absent. Irritability, pallor with anemia, and cephalohematoma comprise the most common physical findings for infants &lt;12 months of age with EDH [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Other important findings include vomiting, a bulging anterior fontanelle, lethargy, coma, or seizures. Seizures and hypotonia are frequent presenting signs in neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/3\">",
"     3",
"    </a>",
"    ]. Associated fever or hemorrhagic shock has been described in up to 10 percent of infants with EDH [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large amounts of intracranial blood can accumulate prior to changes in the neurologic examination. Thus, bradycardia, pupillary changes, and hemiparesis are late findings often associated with rapid neurologic deterioration and poor outcomes despite rapid intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Older children",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the older child, an EDH should be suspected if there is a witnessed deterioration in neurologic status at any time after a head injury. Depending upon the severity of traumatic injury, the child may present with varying degrees of impaired consciousness and Glasgow Coma Score (GCS) (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"     table 2",
"    </a>",
"    ). Often a small EDH is found by computed tomography (CT) of the head in patients who are neurologically intact. In these children, common symptoms include headache, vomiting, or irritability.",
"   </p>",
"   <p>",
"    Other children who present in coma from large hematomas require urgent surgical evacuation. Lateralizing neurologic signs (eg, anisocoria, hemiparesis, hemiplegia) arise from compression of the third cranial nerve and brainstem. These are indicators of progression to cerebral uncal herniation. The side of the dilated pupil matches the side of the hematoma in roughly 90 percent of cases. The constellation of systemic hypertension, bradycardia, and respiratory depression (Cushing triad) is another late sign, and may be a preterminal event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Lucid interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic presentation of an EDH after a temporal head injury is characterized by a lucid interval, where a child initially may have a decreased level of consciousness due to the primary brain injury, then returns to normal level of consciousness for several hours. After this, as the blood accumulates in the epidural space and compresses the brain, the child rapidly deteriorates. However, this type of history is variably present (37 to 67 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. The clinician's goal is to make the diagnosis of EDH BEFORE neurologic deterioration in an asymptomatic or mildly affected child to allow for timely surgical intervention, if needed. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Definitive management'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Posterior fossa EDH findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;EDH in the posterior fossa deserves separate discussion because of significant potential for sudden clinical decompensation with few warning signs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82581 \" href=\"UTD.htm?29/32/30223\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75448 \" href=\"UTD.htm?23/44/24270\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    EDH is located in the posterior fossa in 3 to 17 percent of pediatric cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/1,4,6,7\">",
"     1,4,6,7",
"    </a>",
"    ]. The most common cause is a fall on the occipital region of the head. There is a high association with occipital bone fractures, which are present in 78 to 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. Occipital fractures often cross a dural sinus, resulting in venous hemorrhage and delayed symptoms.",
"   </p>",
"   <p>",
"    Children commonly present with an initial loss of consciousness, headache, and vomiting. Less commonly, there may be dizziness, stiff neck, or pyramidal or cerebellar signs. Children may have a subacute onset of symptoms up to a few days after minor occipital trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/5,10\">",
"     5,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite a relatively benign presentation, these children can deteriorate rapidly with lethal outcomes caused by compression of the brainstem or by hydrocephalus secondary to fourth ventricular obstruction. The limited spatial capacity of the posterior fossa and its vital contents provide the substrate for such grave consequences when an EDH causes mass effect in this region.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PRIMARY EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid overview provides the clinical features, diagnostic evaluation, and emergent management for epidural hematomas in children (",
"    <a class=\"graphic graphic_table graphicRef69494 \" href=\"UTD.htm?15/28/15821\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Initial assessment and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The order of priority in the initial assessment and treatment of the injured child suspected with possible EDH is the same as for any trauma patient (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H9#H9\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Primary survey'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A - Airway maintenance with cervical spine protection",
"     </li>",
"     <li>",
"      B - Breathing and ventilation",
"     </li>",
"     <li>",
"      C - Circulation with hemorrhage control",
"     </li>",
"     <li>",
"      D - Disability (evaluation of neurologic status)",
"     </li>",
"     <li>",
"      E - Exposure (complete",
"      <span class=\"nowrap\">",
"       visualization)/environmental",
"      </span>",
"      control (prevention of hypothermia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A rapid neurologic examination should focus on mental status using an age appropriate GCS (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"     table 2",
"    </a>",
"    ), pupillary findings, cranial nerves, motor function, and cerebellar findings. Patients with concerns for significant intracranial injury or increased intracranial pressure (ICP) must be managed appropriately to reduce the likelihood of secondary brain injury from hypoxia, ischemia, and cerebral edema.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinician should provide supplemental oxygen to keep saturation &gt;95 percent.",
"     </li>",
"     <li>",
"      Cervical spine immobilization should be maintained throughout emergent patient care in all patients in whom there is a concern of cervical spine injury. Those patients with altered mental status should continue to be immobilized even if radiographic studies show no bony abnormality until awake and without neck pain.",
"     </li>",
"     <li>",
"      Head injured patients with compromised airway, inadequate breathing, or severe neurologic findings (GCS &le;8, pupillary abnormalities, neurologic deficit, or rapidly declining mental status) require early rapid sequence endotracheal intubation using measures to prevent increased ICP (",
"      <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"       table 3",
"      </a>",
"      ). Aggressive hyperventilation (PaCO2 &lt;30 mmHg) may cause cerebral ischemia as the result of decreased cerebral blood flow. Consequently, PaCO2 should be maintained between 35 and 40 mmHg unless there are signs of impending herniation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link&amp;anchor=H16#H16\">",
"       \"Initial approach to severe traumatic brain injury in children\", section on 'Rapid sequence intubation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link&amp;anchor=H15#H15\">",
"       \"Elevated intracranial pressure in children\", section on 'Breathing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with hypotension require rapid fluid resuscitation to maintain cerebral perfusion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H12#H12\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Circulation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neurosurgical consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any pediatric trauma patient with a GCS &le;12 (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"     table 2",
"    </a>",
"    ) warrants timely consultation and evaluation by a neurosurgeon. Specific therapies targeted at increased ICP are ideally employed in consultation with a neurosurgeon and include aggressive hyperventilation for signs of impending herniation and osmotic therapy using",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=see_link\">",
"     mannitol",
"    </a>",
"    or hypertonic saline infusion. These treatments are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"     \"Initial approach to severe traumatic brain injury in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;To assess for anemia or coagulopathy and to prepare for surgery, we recommend the following blood studies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count with platelets",
"     </li>",
"     <li>",
"      Prothrombin time (PT)",
"     </li>",
"     <li>",
"      Partial thromboplastin time (PTT)",
"     </li>",
"     <li>",
"      International normalized ratio (INR)",
"     </li>",
"     <li>",
"      Type and cross",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies (eg, AST, ALT, and urinalysis) may be indicated in multiple trauma patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link&amp;anchor=H12#H12\">",
"     \"Initial approach to severe traumatic brain injury in children\", section on 'Laboratory studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lumbar puncture is contraindicated in cases where a space occupying lesion such as EDH is suspected, due to the risk of herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because EDH is potentially life-threatening, there must be an emphasis on early radiographic diagnosis, followed by prompt surgical treatment, if needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Head CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head CT is the mainstay of diagnostic imaging because of the speed with which it can be obtained and interpreted, and its ability to demarcate in detail the extent of the hemorrhage for surgical planning. Outcomes have improved in the post-CT era versus the pre-CT era primarily due to the rapidity of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/6,7,12,13\">",
"     6,7,12,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Operative treatment'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The characteristic appearance of an EDH is a biconvex or lentiform mass that displaces the brain away from the calvarium (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79566 \" href=\"UTD.htm?25/52/26432\">",
"     image 3",
"    </a>",
"    ). As mentioned above, EDH generally does not cross suture lines of the skull. The mass is uniformly hyperdense in two thirds of cases while one-third of cases display mixed hyper- and hypodense areas.",
"   </p>",
"   <p>",
"    The hypodense areas (or \"swirl sign\") typically represents active bleeding or unclotted blood and should not be misinterpreted as chronic blood [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/14\">",
"     14",
"    </a>",
"    ]. A swirl sign usually provides evidence for a rapidly expanding hematoma that requires prompt surgical evacuation.",
"   </p>",
"   <p>",
"    Other important findings seen in association with EDH include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Midline shift",
"     </li>",
"     <li>",
"      Gyral effacement",
"     </li>",
"     <li>",
"      Compression of the lateral ventricle on the side of the hematoma",
"     </li>",
"     <li>",
"      Compression of the basilar cisterns",
"     </li>",
"     <li>",
"      Focal or generalized loss of gray-white differentiation indicating cerebral edema",
"     </li>",
"     <li>",
"      Uncal, subfalcine, or transtentorial herniation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Brain MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the acute setting, an MRI has a very limited role in the diagnosis of an epidural hematoma due to the time constraints within which important clinical decisions need to be made. However, magnetic resonance imaging (MRI) is more sensitive than head CT for the detection of small intracranial hemorrhages [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/15\">",
"     15",
"    </a>",
"    ]. MRI is especially useful in the diagnosis EDH at the vertex [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/16\">",
"     16",
"    </a>",
"    ]. In most centers, MRI is an adjunct to CT in the evaluation of acute head trauma and is used for situations in which there is a strong suspicion for EDH or subdural hematoma, but no clear evidence of hematoma by CT.",
"   </p>",
"   <p>",
"    The MRI signal appearance of EDH and subdural hematoma evolves over time in a manner similar to that observed in parenchymal hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The acute clot is hypointense on T2-weighted images due to the presence of deoxyhemoglobin.",
"     </li>",
"     <li>",
"      Over subsequent weeks, deoxyhemoglobin degrades to methemoglobin, which appears bright on both T1- and T2-weighted images.",
"     </li>",
"     <li>",
"      At several months, only hemosiderin remains, and the clot again becomes hypointense on the T1-weighted images.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral angiography is rarely indicated for the evaluation of EDH in children but may be useful if the EDH is felt to arise from an arteriovenous malformation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DEFINITIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid overview provides the clinical features, diagnostic evaluation, and emergent management for epidural hematomas in children (",
"    <a class=\"graphic graphic_table graphicRef69494 \" href=\"UTD.htm?15/28/15821\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Operative treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with acute EDH, the decision to perform surgery is primarily based upon physical findings and results of head CT. Rapid evaluation and care by a neurosurgeon are key to optimal outcomes. If there is no neurosurgical coverage at the admitting hospital, the child should be resuscitated and promptly transferred to an appropriate institution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Clinical criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon observational studies, common physical findings that indicate the need for EDH evacuation include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/1,4,12,18-20\">",
"     1,4,12,18-20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deterioration in consciousness (GCS &le;8) (",
"      <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"       table 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/18,20\">",
"       18,20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Signs of increased ICP (eg, bradycardia, hypertension, vomiting, headache or irritability) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pupillary abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hemiparesis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cerebellar signs [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/1,12\">",
"       1,12",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"local\" href=\"#H23\">",
"       'Posterior fossa epidural hematoma'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When one or more of these signs are present, the patient should be prepared for an emergent craniotomy. Evidence from small observational studies in adults with acute EDH suggests that morbidity and mortality are decreased when surgery is performed within one to two hours after head trauma, or the onset of neurologic deterioration, for comatose patients (GCS &le;8) with acute EDH and signs of brain herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 34 patients, 18 patients who had evacuation within two hours of onset of coma had a significantly lower mortality and higher rate of intact recovery than those with later surgery (17 versus 56 percent and 67 versus 13 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series of 10 adults with EDH who developed anisocoria, five patients who had craniotomy within 70 minutes after onset of anisocoria survived either intact or with moderate disability. The five patients who had craniotomy &ge;90 minutes after onset of anisocoria died [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Radiographic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the clinical criteria discussed above, the following parameters on head CT suggest the possible need for surgical evacuation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/18,23\">",
"     18,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temporal location (arterial bleeding can lead to rapid decompensation due to uncal herniation and brainstem compression when the hemorrhage is in the temporal fossa)",
"     </li>",
"     <li>",
"      Large size (EDH thickness &gt;10 mm)",
"     </li>",
"     <li>",
"      Midline shift",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, decisions regarding the need for surgical evacuation should not be based solely on radiographic criteria. This is illustrated in a case series of 13 neurologically intact children with significant EDH; 12 patients were successfully managed nonoperatively despite an average EDH thickness of 19 mm on head CT [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/24\">",
"     24",
"    </a>",
"    ]. All but one of these patients was admitted &ge;24 hours after the initial injury, suggesting slow accumulation of the EDH. All patients had full recovery and were normal at follow-up, ranging from 4 months to &gt;10 years after injury. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Nonoperative treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Surgical procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical management of the epidural hematoma should take precedence over the secondary trauma workup once the primary survey has been performed and the patient stabilized. Burr hole placement was used diagnostically prior to the wide availability of head CT but can lead to uncontrollable bleeding if the bleeding source is exposed without adequate exposure to allow for coagulation. For this reason, burr hole placement is not recommended in situations where neurosurgical care is limited or unavailable. Open craniotomy affords a more complete evacuation of the hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the operating room, a skin incision is made to allow for the removal of a bone flap that overlies the hematoma. The hematoma is evacuated and any visible source of hemorrhage is identified and coagulated. After the hematoma has been removed, the dura is sutured to holes drilled at the periphery of the craniotomy and the center of the bone flap to close the epidural space and prevent the hematoma from reaccumulating. The bone flap is replaced and affixed to the skull with either suture or cranial plates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nonoperative treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;If at all possible, the decision to manage EDH nonoperatively should be made in conjunction with a neurosurgeon who understands the subtleties that would distinguish the more benign lesion from one that is a surgical emergency. In instances where neurosurgery is not physically available to the managing physician and transport to a higher level of care poses risk to the patient, phone consultation and remote review of the head CT by a neurosurgeon may assist in guiding proper patient disposition.",
"   </p>",
"   <p>",
"    Candidates for nonoperative management typically are neurologically intact and have small EDH with no worrisome radiographic features. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Clinical criteria'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20\">",
"     'Radiographic criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Children managed nonoperatively should only be observed in a facility where experienced pediatric trained personnel can monitor for neurologic changes. Patients with GCS &le;8 should have continuous intracranial monitoring of ICP during observation (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"     table 2",
"    </a>",
"    ). In addition, 24 hour emergency access to head CT and a properly equipped operating room are essential, as deterioration can occur at any time.",
"   </p>",
"   <p>",
"    In most cases, it is reasonable to repeat a head CT within 24 hours to ensure stable size of the hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/25\">",
"     25",
"    </a>",
"    ]. When enlargement of the hematoma is of significant concern, the head CT should be repeated within a shorter interval. In addition, if there are any neurologic changes during the course of observation, a head CT should be repeated immediately to look for an enlarging hematoma that needs surgical evacuation.",
"   </p>",
"   <p>",
"    Asymptomatic patients with small, nonprogressive epidural hematomas on head CT can be safely discharged from the hospital in 24 to 48 hours after injury. Spontaneous resorption of the hematoma usually occurs within one month of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/4,26\">",
"     4,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Posterior fossa epidural hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical treatment of posterior fossa epidural hematomas involves a suboccipital craniotomy in the region of the fracture with particular attention toward avoiding disturbance of the venous sinuses, which can be quite menacing. Since the advent of prompt diagnosis with CT scanning, results in children after surgical evacuation are favorable [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/1,10,12\">",
"     1,10,12",
"    </a>",
"    ]. However, hemorrhage from the venous sinuses present a significant surgical risk.",
"   </p>",
"   <p>",
"    In asymptomatic children who have small posterior fossa epidural hematomas with minimal mass effect, it is reasonable for a neurosurgeon to observe closely with serial head CTs as long as the potential for rapid deterioration is appreciated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/10,26,27\">",
"     10,26,27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Posterior fossa EDH findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurosurgical follow-up after evacuation of an epidural hematoma usually involves a delayed head CT in about 4 to 6 weeks to ensure that there is no residual or recurrent hemorrhage. Children who have not suffered neurologic deficits can usually resume studies within this timeframe. Returning to contact sports is at the discretion of the neurosurgeon and depends on when",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    expects that the bone at the craniotomy site has healed sufficiently. This time period varies with the age of the child and extent of injury to the bone from the accident.",
"   </p>",
"   <p>",
"    Children with residual neurologic deficits after EDH evacuation should be referred for occupational and physical therapy.",
"   </p>",
"   <p>",
"    Children with iron deficiency anemia from blood loss should receive replacement doses of iron (3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of elemental iron in a single or divided dose for 4 weeks). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link\">",
"     \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic outcome following prompt surgical evacuation of an EDH is often favorable [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/28\">",
"     28",
"    </a>",
"    ]. The crucial factor seems to be minimizing the time between the onset of impaired consciousness and the evacuation of the hematoma. Good neurologic recovery after evacuation is associated with a high GCS at presentation and a pure epidural hematoma without associated lesions. In contrast, death or significant disability is associated with a low GCS at presentation, associated intracranial lesions (eg, subdural hematoma), or pupillary changes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children under the age of five years tend to have lower morbidity and mortality from EDH than older children or adults. This observation may be due to compensatory mechanisms within the brain that allow greater protection against an expanding hematoma; in addition, there is a predominance of low velocity impact falls without associated brain injuries in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of mortality in children with EDH is 2 to 6 percent in the post-CT era [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10808/abstract/6,19\">",
"     6,19",
"    </a>",
"    ]. There is a higher mortality in children who present with a lucid interval because this apparent improvement may delay definitive treatment or transfer of the patient. This association emphasizes the importance of prompt transfer of patients if the admitting institution does not have appropriate neurosurgical coverage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid overview provides the clinical features, diagnostic evaluation, and emergent management for epidural hematomas in children (",
"    <a class=\"graphic graphic_table graphicRef69494 \" href=\"UTD.htm?15/28/15821\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An epidural hematoma (EDH) should be suspected particularly after a head injury in a child who has a loss of consciousness or altered mental status according to their caregiver, although EDH may rarely occur in children with minor head injury. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Physical examination'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=see_link\">",
"       \"Minor head trauma in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In neonates and infants with open fontanelles, clinical signs are nonspecific or may be absent. Irritability, pallor with anemia, and cephalohematoma comprise the most common physical findings for infants &lt;12 months of age with EDH. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Neonates and infants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Temporal EDH classically presents with brief loss of consciousness followed by a lucid interval in older children. Other common signs are headache, vomiting, and irritability. The clinician's goal is to make the diagnosis of EDH BEFORE neurologic deterioration to allow for timely surgical intervention, if needed. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Older children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lateralizing neurologic signs (eg, anisocoria, hemiparesis, hemiplegia) arise from compression of the third cranial nerve and brainstem. These are indicators of progression to cerebral uncal herniation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Older children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The constellation of systemic hypertension, bradycardia, and respiratory depression (Cushing triad) is another late sign, and may be a preterminal event. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Older children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Posterior fossa epidural hematomas can result in a rapid neurologic decline and catastrophic results if not promptly diagnosed and managed. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Posterior fossa epidural hematoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Primary evaluation and management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The order of priority in the initial assessment and treatment of the injured child suspected with possible EDH is the same as for any trauma patient (",
"      <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"       figure 1",
"      </a>",
"      ). A rapid neurologic examination should focus on mental status using an age appropriate GCS (",
"      <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"       table 2",
"      </a>",
"      ), pupillary findings, cranial nerves, motor function, and cerebellar findings. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Initial assessment and treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H9#H9\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Primary survey'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with concerns for significant intracranial injury or increased intracranial pressure (ICP) must be managed appropriately to reduce the likelihood of secondary brain injury from hypoxia, ischemia, and cerebral edema. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Initial assessment and treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"       \"Elevated intracranial pressure in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Any child with a GCS &le;12 (",
"      <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"       table 2",
"      </a>",
"      ) warrants timely consultation and evaluation by a neurosurgeon. Specific therapies targeted at increased ICP are ideally employed in consultation with a neurosurgeon. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Neurosurgical consultation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Head CT is the mainstay of diagnostic imaging because of the speed with which it can be obtained and interpreted, and its ability to demarcate in detail the extent of the hemorrhage for surgical planning. The characteristic appearance of EDH on CT is a biconvex or lentiform hyperdense mass that displaces the brain away from the calvarium and does not cross suture lines (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79566 \" href=\"UTD.htm?25/52/26432\">",
"       image 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Head CT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Definitive management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A child with an acute EDH who has significant physical findings or mass effect on head CT requires operative evacuation. Emergent evaluation and craniotomy by a neurosurgeon is essential (because urgent surgical attention is critical, in remote regions without neurosurgical support, craniotomy by another properly trained practitioner, such as a trauma surgeon, may be reasonable). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Operative treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that neurologically intact children with small EDH be managed nonoperatively (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). They should be monitored for at least 24 hours for any signs of neurologic decline, and a CT scan should be repeated to rule out an expanding hematoma. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Nonoperative treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Good outcome after surgical evacuation is associated with young age, higher GCS at presentation, pure EDH without associated intracranial lesions, and rapid surgical intervention in children with coma or signs of brain herniation. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/1\">",
"      Ciurea AV, Nuteanu L, Simionescu N, Georgescu S. Posterior fossa extradural hematomas in children: report of nine cases. Childs Nerv Syst 1993; 9:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/2\">",
"      Beni-Adani L, Flores I, Spektor S, et al. Epidural hematoma in infants: a different entity? J Trauma 1999; 46:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/3\">",
"      Heyman R, Heckly A, Magagi J, et al. Intracranial epidural hematoma in newborn infants: clinical study of 15 cases. Neurosurgery 2005; 57:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/4\">",
"      Rocchi G, Caroli E, Raco A, et al. Traumatic epidural hematoma in children. J Child Neurol 2005; 20:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/5\">",
"      Peter JC, Domingo Z. Subacute traumatic extradural haematomas of the posterior fossa: a clinicopathological entity of the 5- to 10-year-old child. Childs Nerv Syst 1990; 6:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/6\">",
"      Er��ahin Y, Mutluer S, G&uuml;zelbag E. Extradural hematoma: analysis of 146 cases. Childs Nerv Syst 1993; 9:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/7\">",
"      Pa��ao��lu A, Orhon C, Ko&ccedil; K, et al. Traumatic extradural haematomas in pediatric age group. Acta Neurochir (Wien) 1990; 106:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/8\">",
"      Pillay R, Peter JC. Extradural haematomas in children. S Afr Med J 1995; 85:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/9\">",
"      Choux M, Grisoli F, Peragut JC. Extradural hematomas in children. 104 cases. Childs Brain 1975; 1:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/10\">",
"      Bozbu��a M, Izgi N, Polat G, G&uuml;rel I. Posterior fossa epidural hematomas: observations on a series of 73 cases. Neurosurg Rev 1999; 22:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/11\">",
"      Duffy GP. Lumbar puncture in the presence of raised intracranial pressure. Br Med J 1969; 1:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/12\">",
"      Ammirati M, Tomita T. Posterior fossa epidural hematoma during childhood. Neurosurgery 1984; 14:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/13\">",
"      Neubauer UJ. Extradural haematoma of the posterior fossa. Twelve years experiences with CT-scan. Acta Neurochir (Wien) 1987; 87:105.",
"     </a>",
"    </li>",
"    <li>",
"     Osborne AG. Craniocerebral trauma. In: Diagnostic Neuroradiology, Mosby, St. Louis 1994. p.199.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/15\">",
"      Gentry LR, Godersky JC, Thompson B, Dunn VD. Prospective comparative study of intermediate-field MR and CT in the evaluation of closed head trauma. AJR Am J Roentgenol 1988; 150:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/16\">",
"      Miller DJ, Steinmetz M, McCutcheon IE. Vertex epidural hematoma: surgical versus conservative management: two case reports and review of the literature. Neurosurgery 1999; 45:621.",
"     </a>",
"    </li>",
"    <li>",
"     Victor M, Ropper A. Craniocerebral trauma. In: Adams and Victor's Principles of Neurology, 7th, Victor M, Ropper A.  (Eds), McGraw-Hill, New York 2001. p.925.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/18\">",
"      Schutzman SA, Barnes PD, Mantello M, Scott RM. Epidural hematomas in children. Ann Emerg Med 1993; 22:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/19\">",
"      Jamjoom A, Cummins B, Jamjoom ZA. Clinical characteristics of traumatic extradural hematoma: a comparison between children and adults. Neurosurg Rev 1994; 17:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/20\">",
"      Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of acute epidural hematomas. Neurosurgery 2006; 58:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/21\">",
"      Cohen JE, Montero A, Israel ZH. Prognosis and clinical relevance of anisocoria-craniotomy latency for epidural hematoma in comatose patients. J Trauma 1996; 41:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/22\">",
"      Haselsberger K, Pucher R, Auer LM. Prognosis after acute subdural or epidural haemorrhage. Acta Neurochir (Wien) 1988; 90:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/23\">",
"      Bejjani GK, Donahue DJ, Rusin J, Broemeling LD. Radiological and clinical criteria for the management of epidural hematomas in children. Pediatr Neurosurg 1996; 25:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/24\">",
"      Balmer B, Boltshauser E, Altermatt S, Gobet R. Conservative management of significant epidural haematomas in children. Childs Nerv Syst 2006; 22:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/25\">",
"      Givner A, Gurney J, O'Connor D, et al. Reimaging in pediatric neurotrauma: factors associated with progression of intracranial injury. J Pediatr Surg 2002; 37:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/26\">",
"      Pang D, Horton JA, Herron JM, et al. Nonsurgical management of extradural hematomas in children. J Neurosurg 1983; 59:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/27\">",
"      Kawakami Y, Tamiya T, Tanimoto T, et al. Nonsurgical treatment of posterior fossa epidural hematoma. Pediatr Neurol 1990; 6:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10808/abstract/28\">",
"      Gerlach R, Dittrich S, Schneider W, et al. Traumatic epidural hematomas in children and adolescents: outcome analysis in 39 consecutive unselected cases. Pediatr Emerg Care 2009; 25:164.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6519 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_35_10808=[""].join("\n");
var outline_f10_35_10808=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Neonates and infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Older children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Lucid interval",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Posterior fossa EDH findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PRIMARY EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initial assessment and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neurosurgical consultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Head CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Brain MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DEFINITIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Operative treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Clinical criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Radiographic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Surgical procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nonoperative treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Posterior fossa epidural hematoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Primary evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Definitive management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6519\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6519|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/32/30223\" title=\"diagnostic image 1\">",
"      Posterior fossa epidural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/44/24270\" title=\"diagnostic image 2\">",
"      Occipital fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/52/26432\" title=\"diagnostic image 3\">",
"      Epidural hematoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6519|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/51/43834\" title=\"figure 1\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6519|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/28/15821\" title=\"table 1\">",
"      Rapid overview Epidural hematoma in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/58/2989\" title=\"table 2\">",
"      Glasgow and pediatric coma scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/26/17837\" title=\"table 3\">",
"      Rapid overview of rapid sequence intubation in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=related_link\">",
"      Initial approach to severe traumatic brain injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19112?source=related_link\">",
"      Intracranial epidural hematoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11222?source=related_link\">",
"      Intracranial epidural hematoma in children: Epidemiology, anatomy and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=related_link\">",
"      Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=related_link\">",
"      Minor head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_35_10809="Embolism from aortic plaque: Thromboembolism";
var content_f10_35_10809=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Embolism from aortic plaque: Thromboembolism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/35/10809/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/35/10809/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/35/10809/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/35/10809/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/35/10809/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/35/10809/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/35/10809/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/35/10809/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/35/10809/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/35/10809/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic atherosclerotic plaques are a manifestation of systemic atherosclerosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72777 \" href=\"UTD.htm?20/39/21104\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef76326 \" href=\"UTD.htm?18/15/18686\">",
"     movie 1",
"    </a>",
"    ). They are associated with risk factors for atherosclerotic disease, and are more common in patients with coronary artery disease and in older individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. In addition, aortic atherosclerotic plaques are an important cause of systemic embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. Embolic events in the setting of aortic atherosclerosis can occur spontaneously or they can be induced by mechanical interventions including guidewire manipulation during cardiac catheterization, intraaortic balloon pulsations, and vessel",
"    <span class=\"nowrap\">",
"     clamping/manipulations",
"    </span>",
"    during cardiac and vascular surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The risk of embolism in patients with aortic atherosclerosis is markedly increased for plaques that are mobile",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    protruding, particularly if &gt;4 mm in thickness.",
"   </p>",
"   <p>",
"    The clinical features, prevention, and treatment of thromboembolism from aortic plaques will be reviewed here, with a focus on stroke, which is the most common clinical manifestation. Atheroembolism is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H536302420\">",
"    <span class=\"h1\">",
"     THROMBOEMBOLISM VERSUS ATHEROEMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboembolism from aortic plaques is common, whereas cholesterol crystal embolization is fairly rare. Although there is some overlap, these disorders have characteristic distinguishing features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thromboembolism may occur when an atherosclerotic plaque from large or medium arteries becomes unstable, and superimposed thrombi embolize. The thromboemboli tend to be single, and tend to lodge in small or medium arteries, resulting most often in stroke or transient ischemic attack [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/6-9,12\">",
"       6-9,12",
"      </a>",
"      ]. Limb ischemia (upper or lower extremity), renal infarction, intestinal ischemia, or ischemia of other organs can also occur [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/9,13\">",
"       9,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The term atheroembolism is used synonymously with cholesterol crystal embolism, cholesterol embolism or micro-atheroembolism. These terms refer to arterio-arterial embolism of fragments of atheromatous material originating from an atherosclerotic plaque of the aorta or occasionally other arteries. The result of such embolization is tissue and organ damage produced by multiple small artery occlusions (eg, \"blue toe\" syndrome, retinal ischemia, renal failure, livedo reticularis, and intestinal infarction). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"       \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The material protruding from the aortic wall is typically atheromatous plaque, with the characteristic composition consisting of a lipid pool, a fibrous cap, smooth muscle cell and mononuclear cell infiltration, and varying degrees of calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/7,14\">",
"     7,14",
"    </a>",
"    ]. Thrombi may be more characteristic of plaques with a high proportion of lipid and with a preponderance of monocytes or macrophages as compared with smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/14\">",
"     14",
"    </a>",
"    ]. The mobile component, as seen on transesophageal echocardiography (TEE), is usually thrombus superimposed on the plaque, which has presumably ruptured (",
"    <a class=\"graphic graphic_movie graphicRef61705 \" href=\"UTD.htm?4/35/4671\">",
"     movie 2",
"    </a>",
"    ). In contrast, highly calcified plaques may be more",
"    <span class=\"nowrap\">",
"     stable/less",
"    </span>",
"    \"vulnerable,\" that is, less likely to develop thrombus and embolize [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Plaque ulceration and mobility'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMPLEX AORTIC PLAQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atherosclerosis of the aorta is a diffuse process and many of the individual plaques are complex, which is defined as thickness &gt;4 mm, or ulceration, or either mobility or pedunculation of a component of the plaque. In one series of patients with complex thoracic aortic plaque, mobile thrombi were seen on TEE in 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/16\">",
"     16",
"    </a>",
"    ]. Discovery of complex aortic plaque may occur when TEE is performed as part of the evaluation for an acute stroke or peripheral embolism, or for some unrelated reason.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Association with embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence for a cause and effect relationship between complex aortic plaque and embolism comes from the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complex aortic plaque is seen in 2 to 14 percent of patients with a history of stroke or peripheral embolization [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/3,8,17\">",
"       3,8,17",
"      </a>",
"      ]. This may be an underestimate of the true prevalence as the plaque that may have \"caused\" the event has migrated and only \"residual\" plaque is present.",
"     </li>",
"     <li>",
"      Complex thoracic aortic plaque is seen much more frequently in stroke patients compared with controls without stroke in both TEE and autopsy studies (21 to 27 percent versus 5 to 9 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/7,8,12,17\">",
"       7,8,12,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Complex thoracic aortic plaques are associated with a high frequency of embolization [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/9,13,16\">",
"       9,13,16",
"      </a>",
"      ]. In a prospective observational cohort study of over 500 patients who underwent TEE, 42 patients were identified as having a complex thoracic aortic plaque and no other detected source of emboli [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/13\">",
"       13",
"      </a>",
"      ]. Among these patients, strokes occurred in 12 percent and peripheral emboli in 21 percent, compared with embolization in only 7 percent in patients without plaque during a mean follow-up of 14 months.",
"     </li>",
"     <li>",
"      Aortic plaques are strongly associated with embolic stroke even in patients with atrial fibrillation. This was illustrated in a subset analysis of the Stroke Prevention in Atrial Fibrillation III (SPAF-III) trial in which 134 of 382 patients (35 percent) with atrial fibrillation were identified as having a complex aortic plaque (&gt;4 mm in thickness or mobile) on TEE [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/18\">",
"       18",
"      </a>",
"      ]. The stroke rate at one year was significantly higher for patients with complex aortic plaque (15.8 versus 8.0 and 1.2 percent with simple or no plaque, respectively). Complex aortic plaque was independently associated with being in a higher risk (of embolization) group [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=see_link&amp;anchor=H18#H18\">",
"       \"Secondary prevention for specific causes of ischemic stroke and transient ischemic attack\", section on 'Aortic atherosclerosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk factors for embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of embolization from aortic plaques and the organs affected are related to the characteristics of the plaque on TEE, including plaque thickness, ulceration, mobility, and location, and to instrumentation during cardiovascular procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Plaque thickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thicker plaques are more likely to be lipid-laden and to have overlying thrombi and embolize [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/8,9,15,20\">",
"     8,9,15,20",
"    </a>",
"    ]. The potential importance of plaque thickness is illustrated by the following two studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case control study, 250 patients with ischemic stroke were compared with 250 controls undergoing TEE for cardiac evaluation. Among patients with stroke, 14.4 percent had plaques &gt;4 mm in thickness in the ascending aorta or aortic arch compared to only 2 percent of controls [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/8\">",
"       8",
"      </a>",
"      ]. Compared with plaque thickness &lt;1 mm, the adjusted odds ratio was 4.2 and 9.1 for plaques 1 to 3.9 mm and &gt;4 mm, respectively.",
"     </li>",
"     <li>",
"      A subsequent prospective study from the French Study of Aortic Plaques in Stroke Group included 331 patients with an initial ischemic stroke who underwent TEE [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/9\">",
"       9",
"      </a>",
"      ]. At two to four years of follow-up:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The incidence of recurrent stroke was 2.8, 3.5, and 11.9 percent per year for patients with plaque thickness &lt;1, 1 to 3.9, and &gt;4 mm.",
"     </li>",
"     <li>",
"      The incidence of all vascular events was 5.9, 9.1 and 26 percent per year for patients with plaque thickness &lt;1, 1 to 3.9 and &gt;4 mm.",
"     </li>",
"     <li>",
"      After adjustment for carotid artery stenosis, atrial fibrillation, peripheral vascular disease, and other risk factors, aortic plaques &gt;4 mm were independent predictors of recurrent ischemic stroke (relative risk 3.8; 95% CI 1.8-7.8).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A different conclusion was reached in an analysis from the Stroke Prevention: Assessment of Risk in a Community (SPARC) study which found that complex aortic plaque (&gt;4 mm or mobile) was not associated with a significant increase in risk of cerebrovascular events after adjusting for age, gender, and other clinical risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/21\">",
"     21",
"    </a>",
"    ]. The reason for this apparent disparity may be related to patient selection bias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Plaque ulceration and mobility",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an autopsy study of 500 consecutive patients with cerebrovascular and other neurologic diseases, ulcerated aortic arch plaques were much more common in those with cerebrovascular disease (16.9 versus 5.1 percent in those with other neurologic diseases), particularly in the 28 patients with no other known cause for stroke such as atrial fibrillation (58 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Protruding or pedunculated plaques, compared to flat or layered, are associated with a higher risk of embolic events [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/13,17,22,23\">",
"     13,17,22,23",
"    </a>",
"    ]. This was illustrated in a study of 36 patients with aortic plaque on TEE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/22\">",
"     22",
"    </a>",
"    ]. The plaque was pedunculated and mobile in 11 patients (31 percent), and layered and immobile in 25 (69 percent). Embolic events occurred more frequently in those with pedunculated plaques (8 of 11 versus 3 of 25 [73 versus 12 percent]). These mobile thrombi can occasionally be very large (",
"    <a class=\"graphic graphic_movie graphicRef61705 \" href=\"UTD.htm?4/35/4671\">",
"     movie 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In patients with mobile aortic plaques, the mobile component has been shown to be primarily thrombus either by direct examination during aortic or cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/24,25\">",
"     24,25",
"    </a>",
"    ] or by pathologic examination of tissue obtained during surgery or at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Resolution of mobile aortic masses with anticoagulation and fibrinolytic therapy lends further support to the role of thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Plaque location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although embolization can be a complication of lesions at any site in the aorta, stroke will occur only with lesions of the ascending aorta and aortic arch. In a study cited above, the odds ratio for stroke was 13.8 for patients with plaques &gt;4 mm in the aortic arch compared to 1.5 with such lesions in the descending aorta (",
"    <a class=\"graphic graphic_figure graphicRef61664 \" href=\"UTD.htm?35/12/36045\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/8\">",
"     8",
"    </a>",
"    ]. In the absence of severe aortic regurgitation, descending aortic lesions generally do not embolize retrograde to the brain; thus, the increased risk may reflect increased atherosclerotic burden.",
"   </p>",
"   <p>",
"    Mobile thrombi may be seen in different locations in the same patient at different times. Complex plaques more commonly involve the mid or distal aortic arch or descending aorta, and are relatively uncommon in the ascending aorta. This results in a higher likelihood of embolic events involving the left cerebral hemisphere or the peripheral circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cardiovascular procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboembolism due to dislodging of debris from the aortic wall may occur as a complication of invasive cardiovascular procedures (eg, diagnostic catheterization, percutaneous coronary intervention, intraaortic balloon pump, cardiac surgery) when a catheter or wire is advanced in a retrograde fashion from the femoral artery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/10,11,31-34\">",
"     10,11,31-34",
"    </a>",
"    ]. Manipulation of the aorta (cross clamping and performance of the proximal anastomosis) is also thought to predispose to embolization due to mechanical disruption of the atheroma. These procedures also increase the risk of atheroembolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 70 patients with aortic plaque &ge;5 mm on TEE, the rate of embolic events was 17 percent after cardiac catheterization via the femoral artery [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/10\">",
"       10",
"      </a>",
"      ]. In comparison, there were no embolic events in those (11 patients) catheterized via the brachial route. In addition, embolic events occurred in 5 of 10 patients with complex aortic plaque treated with an intraaortic balloon pump, compared to no events in 12 patients without complex aortic plaque.",
"     </li>",
"     <li>",
"      In an analysis of 130 patients &ge;65 years of age undergoing coronary artery bypass grafting, protruding aortic arch plaques were identified in 23 patients (18 percent), 12 of whom had mobile plaques [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/11\">",
"       11",
"      </a>",
"      ]. The risk of stroke was much higher in those with mobile plaques (3 of 12 versus 2 of 118).",
"     </li>",
"     <li>",
"      In a series of 3404 patients undergoing cardiac surgery with cardiopulmonary bypass, intraoperative TEE revealed complex aortic arch plaque (&ge;5 mm thick",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mobile) in 268 (8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/34\">",
"       34",
"      </a>",
"      ]. Stroke occurred in 12 percent of these patients, six-fold higher than the overall intraoperative stroke risk at that institution. Patients who underwent aortic arch atherectomy in an effort to reduce the stroke risk actually had a higher rate of stroke (35 percent). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Surgery'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3834?source=see_link&amp;anchor=H3#H3\">",
"       \"Neurologic complications of cardiac surgery\", section on 'Stroke'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3834?source=see_link&amp;anchor=H7#H7\">",
"       \"Neurologic complications of cardiac surgery\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations depend upon the arterial segment affected by thromboembolism. In the retrospective cohort study of 519 patients with complex thoracic aortic plaque cited above, the most common manifestations were stroke (50 percent), transient ischemic attack (35 percent), and signs and symptoms of peripheral emboli (14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/16\">",
"     16",
"    </a>",
"    ]. Milder forms of cerebral damage (eg, cognitive dysfunction) may be another consequence of embolization from the aorta during cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/35\">",
"     35",
"    </a>",
"    ]. The discussion of the differential diagnosis of stroke is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=see_link\">",
"     \"Clinical diagnosis of stroke subtypes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=see_link\">",
"     \"Cryptogenic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complex plaques more commonly involve the mid or distal aortic arch or descending aorta, and are relatively uncommon in the ascending aorta. This results in a higher likelihood of embolic events involving the left cerebral hemisphere or the peripheral circulation than embolic events in the innominate artery distribution (eg, right brain) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=see_link\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=see_link\">",
"     \"Acute mesenteric ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With thromboembolic events, multiple sites may be simultaneously involved (eg, ischemic colitis, acute renal injury, lower extremity ischemia, visual loss), but this is less common compared with cholesterol embolization, which is typically characterized by showers of small emboli. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality associated with complex aortic plaque may be as high as 20 percent within three years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/16\">",
"     16",
"    </a>",
"    ]. Almost 20 percent of the deaths are attributed to stroke, and an additional 7 percent to other embolic events (eg, ischemic colitis). In addition, in-hospital mortality following cardiac surgery was, in one series, 15 percent overall and as high as 39 percent with intraoperative stroke during cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging techniques used for detection of aortic plaques have included TEE, computed tomography (CT), magnetic resonance imaging (MRI), and transthoracic echocardiography. Thoracic aortic plaque (and especially plaque mobility) is best identified with TEE. Discovery of a complex aortic plaque (&gt;4 mm thick, or mobile, ulcerated, or pedunculated) may occur when TEE is performed as part of the evaluation for an acute stroke, peripheral embolism, or for some unrelated reason. The role of CT or MRI is not well established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;TEE is the procedure of choice for the detection and measurement of thoracic aortic plaques and of cardiac sources of embolization (",
"    <a class=\"graphic graphic_movie graphicRef76326 \" href=\"UTD.htm?18/15/18686\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef61705 \" href=\"UTD.htm?4/35/4671\">",
"     movie 2",
"    </a>",
"    ). It is moderately invasive but has a very low complication rate. Conscious sedation is required in most patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=see_link\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The accuracy of TEE in detecting and characterizing aortic plaque was illustrated in a report in which TEE was performed during surgery in 31 patients undergoing repair of an aortic aneurysm or dissection, with the tissue later examined pathologically [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/26\">",
"     26",
"    </a>",
"    ]. TEE and pathologic evaluation were in agreement in distinguishing minimal intimal thickening from more severe plaques in 93 percent of the 62 aortic segments examined. TEE also had a high sensitivity and specificity for the detection of thrombus (91 and 90 percent, respectively).",
"   </p>",
"   <p>",
"    In some patients with thromboembolism from aortic plaque, transthoracic echocardiography may demonstrate the plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/36\">",
"     36",
"    </a>",
"    ]. However, its sensitivity is limited since resolution is insufficient for measuring the prognostically important plaque thickness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other imaging techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT and MRI of the chest can also be used to detect aortic plaques, but experience is more limited and plaque mobility cannot be readily characterized. There is no established role for these imaging techniques in the detection or evaluation of aortic plaque.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noncoronary atherosclerotic disease is a coronary heart disease risk equivalent and, as such, all patients with established atherosclerotic aortic plaque, including those who are asymptomatic, should be aggressively treated to prevent future cardiovascular events. These therapies include antithrombotic therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ), lipid-lowering therapy (eg, statins), blood pressure control, smoking cessation, and in patients with diabetes, glycemic control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate issue is whether specific therapy might prevent a first or recurrent embolization from atherosclerotic plaques in the aorta. Both medical and surgical approaches have been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89902933\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether specific medical therapy might prevent a first or recurrent embolization from atherosclerotic plaques in the aorta remains controversial. The mainstays of medical treatment are antithrombotic therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) and lipid-lowering therapy (statins). The role of other antiplatelet agents (eg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    ) alone or in addition to aspirin or warfarin is unknown, and these alternatives should only be used for those who are not candidates for warfarin or aspirin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89901660\">",
"    <span class=\"h3\">",
"     Antithrombotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment for the prevention of ischemic stroke and TIA due to aortic disease is not clear.",
"   </p>",
"   <p>",
"    A beneficial effect of anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    was suggested by several uncontrolled studies of primary and secondary atherosclerosis prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/18,28,37,38\">",
"     18,28,37,38",
"    </a>",
"    ]. These studies demonstrated a significant risk of stroke in patients with aortic plaque who were not treated with adequate warfarin therapy. The SPAF-III trial compared adjusted-dose warfarin (to maintain an international normalized ratio [INR] of 2 to 3) to low-dose warfarin [INR 1.2-1.5] plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for the prevention of stroke in 1044 patients with atrial fibrillation with at least one thromboembolic risk factor (heart failure or left ventricular fractional shortening &le;25 percent, previous thromboembolism, systolic blood pressure &gt;160 mmHg, or female &gt;75 years of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/37\">",
"     37",
"    </a>",
"    ]. A subset patients (n = 382) underwent observational TEE; in each treatment group, 35 percent of patients had complex aortic plaque (&gt;4 mm, mobile, ulcerated or pedunculated), of which approximately half were in the ascending or transverse aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/18\">",
"     18",
"    </a>",
"    ]. At a mean follow-up of 1.1 years, the incidence of stroke in patients with complex aortic plaque was 4 percent in those treated with adjusted-dose warfarin (median INR 2.3) compared with 16 percent for those on fixed low-dose warfarin plus aspirin. The risk reduction (75 percent) was the same as in the entire study population, but the absolute benefit was greater (12 versus 6 percent) because patients with complex plaque were at higher risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar benefits were noted in two smaller observational studies that evaluated the possible efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for secondary prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/28,38\">",
"     28,38",
"    </a>",
"    ]. In the larger series, 129 patients who had undergone TEE for stroke, other embolic events, planned cardioversion, or other reasons had protruding aortic plaque [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/38\">",
"     38",
"    </a>",
"    ]. All patients were treated at the discretion of their physician with antiplatelet agents or oral anticoagulants (54 and 46 percent, respectively). Among those with protruding plaque, there were no embolic events in the 27 patients treated with anticoagulation; in comparison, clinical embolic events occurred in 5 of 23 patients treated with antiplatelet therapy.",
"   </p>",
"   <p>",
"    In contrast to these findings, no statistically significant benefit was noted with anticoagulation in a retrospective analysis of 519 patients with complex (&gt;4 mm) thoracic aortic plaque on TEE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An international randomized trial comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in patients with complex aortic plaques is underway Europe and Australia (the ARCH trial) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Lipid-lowering therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins are reasonable in all patients with complex aortic plaque, as well as patients with simple plaque and a history of otherwise unexplained stroke or peripheral embolism, since such plaques represent systemic atherosclerosis. Statins have a variety of potentially beneficial mechanisms, including antiinflammatory properties that may be applicable to aortic plaques. We recommend statin therapy for all patients with complex aortic plaque, as well as patients with simple plaque and a history of otherwise unexplained stroke or peripheral embolism. The optimal goal LDL in patients without a prior stroke has not been established. We suggest using the same targets recommended for the secondary prevention of coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of statin therapy in reducing the risk of embolic events in patients with thoracic aortic atherosclerosis has been evaluated only in observational studies. In the previously cited retrospective analysis of 519 patients (64 percent of whom had a history of coronary heart disease), statin therapy was associated with a significant 17 percent absolute reduction in thromboembolic events (12 versus 29 percent in patients not treated with a statin) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/16\">",
"     16",
"    </a>",
"    ]. This apparent clinical benefit probably reflects, at least in part, stabilization or even regression of aortic plaque [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/40-44\">",
"     40-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89902724\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;After considering the available incidence and pending the results of the randomized ARCH trial, we use the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with no contraindications (ie, low risk of major bleeding) with stroke and complex aortic plaque (&ge;4 mm thick",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      atheroma with a mobile component), or without stroke but atheroma with a mobile component, lipid-lowering therapy plus either chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy or chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (81 to 325 mg daily) are appropriate. The goal INR in patients for whom warfarin therapy has been chosen has not been studied. It seems reasonable to use the same values recommended for atrial fibrillation (INR 2.0 to 3.0).",
"     </li>",
"     <li>",
"      The optimal approach for patients without stroke and simple plaque (&lt;4 mm without a mobile component) and no complex atheroma is controversial because the data are limited. Lipid-lowering therapy plus chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy (INR 2.0-3.0) may be warranted if there has been an embolic event (eg, peripheral embolism); otherwise, lipid-lowering therapy and chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy (81 to 325 mg daily) are likely adequate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our recommendations are generally consistent with the American College of Chest Physicians guidelines for antithrombotic and thrombolytic therapy for valvular disease, ischemic stroke, and peripheral artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. However, in contrast to the 2008 guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/48\">",
"     48",
"    </a>",
"    ], the 2012 ACCP guidelines concluded there is insufficient evidence to support the use of antithrombotic therapy for prevention of ischemic events in patients with complex thoracic aortic atheroma, suggesting that patients with aortic atheroma and thromboembolism with no other identifiable source be managed in the same way as those with no aortic atheromatous disease (ie, long-term antiplatelet therapy, no role for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of surgical therapy to prevent embolization in patients with aortic plaque is not clearly defined. Randomized trials and large observational studies suggest that, among patients with atherosclerosis who undergo coronary artery bypass graft surgery (CABG), the rate of stroke is reduced with minimally invasive off-pump CABG. The use of intraoperative ultrasound (epicardial or TEE) to direct the sites of aortic manipulation also may be beneficial. The data supporting these conclusions are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2168?source=see_link&amp;anchor=H7#H7\">",
"     \"Prevention of neurologic complications of cardiac surgery\", section on 'Minimally invasive surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2168?source=see_link&amp;anchor=H13#H13\">",
"     \"Prevention of neurologic complications of cardiac surgery\", section on 'Intraoperative monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients undergoing cardiac surgery, prophylactic replacement of the aortic arch and aortic arch atherectomy are other procedures that have been evaluated. Aortic arch replacement may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/49\">",
"     49",
"    </a>",
"    ], but prophylactic atherectomy may result in worse outcomes. In one report, aortic arch atherectomy was performed during surgery in an effort to reduce the stroke risk in 268 patients with &gt;4 mm aortic plaque [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/34\">",
"     34",
"    </a>",
"    ]. These patients had a higher rate of stroke than those in whom atherectomy was not performed (35 versus 12 percent).",
"   </p>",
"   <p>",
"    Aortic arch atherectomy has been performed with good results in the rare younger patient who is a good operative candidate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. However, this should be considered an experimental approach. We have had mixed results with this approach and only consider atherectomy when the plaque is highly mobile and very large or there has been further growth despite medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89901908\">",
"    <span class=\"h3\">",
"     Endovascular surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular stenting to manage atheroembolic disease has been reported primarily for the treatment of abdominal aortic sources [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. The stent-graft is positioned overlying the atheromatous plaque to exclude it from the circulation, thus preventing subsequent embolization. A case report describes the successful deployment of a thoracic stent-graft to manage a thoracic aortic atheromatous lesion that was the source for massive distal embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10809/abstract/54\">",
"     54",
"    </a>",
"    ]. The endovascular approach is an attractive option for patients who are poor candidates for surgery; however, potential disadvantages include the potential for iatrogenic embolization due to manipulation of catheters in the region of the lesion, and complications related to intravenous contrast.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thoracic aortic atherosclerotic plaques are an important potential source of systemic emboli (thromboembolus, atheroembolus), leading to stroke, transient ischemic attack, and embolization to other arterial beds. The clinical manifestations of thromboembolism tend to differ from those of atheroembolism. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H536302420\">",
"       'Thromboembolism versus atheroembolism'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"       \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of thromboembolism in patients with aortic atherosclerosis is markedly increased when there is complex plaque, which is defined as thickness &gt;4 mm, ulceration, or either mobility or pedunculation of a component. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk factors for embolization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with aortic atherosclerosis with or without a history of otherwise unexplained stroke or peripheral embolism should be treated for secondary prevention of cardiovascular disease. These therapies include antithrombotic therapy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ), lipid-lowering therapy (eg, statin), blood pressure control, smoking cessation, and, in patients with diabetes, glycemic control. Two preventive therapies that are potentially beneficial for the prevention of a first or a recurrent stroke are antithrombotic agents and aggressive lipid-lowering with statins (with targets lower than those for primary prevention). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"       \"Secondary prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The benefit of antithrombotic therapy for aortic arch plaque with or without stroke is uncertain, given limited observational data and the absence of randomized trials. Although the optimal LDL-cholesterol target is unknown for this population, we believe that using targets similar to those recommended for the secondary prevention of coronary artery disease is appropriate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"       \"Secondary prevention of cardiovascular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For eligible patients (ie, low risk of major bleeding) with stroke and complex aortic plaque (&gt;4 mm thick",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      atheroma with a mobile component) or without stroke but atheroma with a mobile component, chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy (INR 2.0-3.0) plus a statin, or chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      daily (81 to 325 mg) plus statin therapy may be appropriate. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=see_link&amp;anchor=H18#H18\">",
"       \"Secondary prevention for specific causes of ischemic stroke and transient ischemic attack\", section on 'Aortic atherosclerosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although prophylactic surgery for the management of atherosclerotic plaque has been performed, there is no evidence of benefit. Among patients undergoing cardiac surgery or aortic surgery at risk for aortic atherosclerosis, intraoperative ultrasound may be beneficial to help to guide sites of aortic manipulation or clamping; the use of off-pump CABG may also be beneficial. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105343967\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to acknowledge Dr. Paul Tunick, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/1\">",
"      Fazio GP, Redberg RF, Winslow T, Schiller NB. Transesophageal echocardiographically detected atherosclerotic aortic plaque is a marker for coronary artery disease. J Am Coll Cardiol 1993; 21:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/2\">",
"      Matsuzaki M, Ono S, Tomochika Y, et al. Advances in transesophageal echocardiography for the evaluation of atherosclerotic lesions in thoracic aorta--the effects of hypertension, hypercholesterolemia, and aging on atherosclerotic lesions. Jpn Circ J 1992; 56:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/3\">",
"      Agmon Y, Khandheria BK, Meissner I, et al. Independent association of high blood pressure and aortic atherosclerosis: A population-based study. Circulation 2000; 102:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/4\">",
"      Jaffer FA, O'Donnell CJ, Larson MG, et al. Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2002; 22:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/5\">",
"      Agmon Y, Khandheria BK, Meissner I, et al. C-reactive protein and atherosclerosis of the thoracic aorta: a population-based transesophageal echocardiographic study. Arch Intern Med 2004; 164:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/6\">",
"      Tunick PA, Kronzon I. Atheromas of the thoracic aorta: clinical and therapeutic update. J Am Coll Cardiol 2000; 35:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/7\">",
"      Amarenco P, Duyckaerts C, Tzourio C, et al. The prevalence of ulcerated plaques in the aortic arch in patients with stroke. N Engl J Med 1992; 326:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/8\">",
"      Amarenco P, Cohen A, Tzourio C, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994; 331:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/9\">",
"      Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. The French Study of Aortic Plaques in Stroke Group. N Engl J Med 1996; 334:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/10\">",
"      Karalis DG, Quinn V, Victor MF, et al. Risk of catheter-related emboli in patients with atherosclerotic debris in the thoracic aorta. Am Heart J 1996; 131:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/11\">",
"      Katz ES, Tunick PA, Rusinek H, et al. Protruding aortic atheromas predict stroke in elderly patients undergoing cardiopulmonary bypass: experience with intraoperative transesophageal echocardiography. J Am Coll Cardiol 1992; 20:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/12\">",
"      Jones EF, Kalman JM, Calafiore P, et al. Proximal aortic atheroma. An independent risk factor for cerebral ischemia. Stroke 1995; 26:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/13\">",
"      Tunick PA, Rosenzweig BP, Katz ES, et al. High risk for vascular events in patients with protruding aortic atheromas: a prospective study. J Am Coll Cardiol 1994; 23:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/14\">",
"      Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/15\">",
"      Cohen A, Tzourio C, Bertrand B, et al. Aortic plaque morphology and vascular events: a follow-up study in patients with ischemic stroke. FAPS Investigators. French Study of Aortic Plaques in Stroke. Circulation 1997; 96:3838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/16\">",
"      Tunick PA, Nayar AC, Goodkin GM, et al. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol 2002; 90:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/17\">",
"      Tunick PA, Perez JL, Kronzon I. Protruding atheromas in the thoracic aorta and systemic embolization. Ann Intern Med 1991; 115:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/18\">",
"      Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med 1998; 128:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/19\">",
"      Zabalgoitia M, Halperin JL, Pearce LA, et al. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998; 31:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/20\">",
"      Mitusch R, Doherty C, Wucherpfennig H, et al. Vascular events during follow-up in patients with aortic arch atherosclerosis. Stroke 1997; 28:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/21\">",
"      Meissner I, Khandheria BK, Sheps SG, et al. Atherosclerosis of the aorta: risk factor, risk marker, or innocent bystander? A prospective population-based transesophageal echocardiography study. J Am Coll Cardiol 2004; 44:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/22\">",
"      Karalis DG, Chandrasekaran K, Victor MF, et al. Recognition and embolic potential of intraaortic atherosclerotic debris. J Am Coll Cardiol 1991; 17:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/23\">",
"      Laperche T, Laurian C, Roudaut R, Steg PG. Mobile thromboses of the aortic arch without aortic debris. A transesophageal echocardiographic finding associated with unexplained arterial embolism. The Filiale Echocardiographie de la Soci&eacute;t&eacute; Fran&ccedil;aise de Cardiologie. Circulation 1997; 96:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/24\">",
"      Tunick PA, Culliford AT, Lamparello PJ, Kronzon I. Atheromatosis of the aortic arch as an occult source of multiple systemic emboli. Ann Intern Med 1991; 114:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/25\">",
"      Tunick PA, Lackner H, Katz ES, et al. Multiple emboli from a large aortic arch thrombus in a patient with thrombotic diathesis. Am Heart J 1992; 124:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/26\">",
"      Vaduganathan P, Ewton A, Nagueh SF, et al. Pathologic correlates of aortic plaques, thrombi and mobile \"aortic debris\" imaged in vivo with transesophageal echocardiography. J Am Coll Cardiol 1997; 30:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/27\">",
"      Khatibzadeh M, Mitusch R, Stierle U, et al. Aortic atherosclerotic plaques as a source of systemic embolism. J Am Coll Cardiol 1996; 27:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/28\">",
"      Dressler FA, Craig WR, Castello R, Labovitz AJ. Mobile aortic atheroma and systemic emboli: efficacy of anticoagulation and influence of plaque morphology on recurrent stroke. J Am Coll Cardiol 1998; 31:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/29\">",
"      Hausmann D, Gulba D, Bargheer K, et al. Successful thrombolysis of an aortic-arch thrombus in a patient after mesenteric embolism. N Engl J Med 1992; 327:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/30\">",
"      Freedberg RS, Tunick PA, Culliford AT, et al. Disappearance of a large intraaortic mass in a patient with prior systemic embolization. Am Heart J 1993; 125:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/31\">",
"      Keeley EC, Grines CL. Scraping of aortic debris by coronary guiding catheters: a prospective evaluation of 1,000 cases. J Am Coll Cardiol 1998; 32:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/32\">",
"      Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002; 105:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/33\">",
"      Henriques JP, Zijlstra F, Ottervanger JP, et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J 2002; 23:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/34\">",
"      Stern A, Tunick PA, Culliford AT, et al. Protruding aortic arch atheromas: risk of stroke during heart surgery with and without aortic arch endarterectomy. Am Heart J 1999; 138:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/35\">",
"      van Dijk D, Keizer AM, Diephuis JC, et al. Neurocognitive dysfunction after coronary artery bypass surgery: a systematic review. J Thorac Cardiovasc Surg 2000; 120:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/36\">",
"      Weinberger J, Azhar S, Danisi F, et al. A new noninvasive technique for imaging atherosclerotic plaque in the aortic arch of stroke patients by transcutaneous real-time B-mode ultrasonography: an initial report. Stroke 1998; 29:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/37\">",
"      Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/38\">",
"      Ferrari E, Vidal R, Chevallier T, Baudouy M. Atherosclerosis of the thoracic aorta and aortic debris as a marker of poor prognosis: benefit of oral anticoagulants. J Am Coll Cardiol 1999; 33:1317.",
"     </a>",
"    </li>",
"    <li>",
"     Aortic Arch Related Cerebral Hazard Trial (ARCH). www.clinicaltrials.gov/ct/show/NCT00235248 (Accessed on February 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/40\">",
"      Lima JA, Desai MY, Steen H, et al. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation 2004; 110:2336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/41\">",
"      Yonemura A, Momiyama Y, Fayad ZA, et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol 2005; 45:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/42\">",
"      Pitsavos CE, Aggeli KI, Barbetseas JD, et al. Effects of pravastatin on thoracic aortic atherosclerosis in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 1998; 82:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/43\">",
"      Corti R, Fuster V, Fayad ZA, et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005; 46:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/44\">",
"      Herrera CJ, Frazin LJ, Dau PC, et al. Atherosclerotic plaque evolution in the descending thoracic aorta in familial hypercholesterolemic patients. A transesophageal echo study. Arterioscler Thromb 1994; 14:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/45\">",
"      Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e601S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/46\">",
"      Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e669S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/47\">",
"      Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e576S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/48\">",
"      Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:630S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/49\">",
"      Wareing TH, Davila-Roman VG, Daily BB, et al. Strategy for the reduction of stroke incidence in cardiac surgical patients. Ann Thorac Surg 1993; 55:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/50\">",
"      Dougherty MJ, Calligaro KD. Endovascular treatment of embolization of aortic plaque with covered stents. J Vasc Surg 2002; 36:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/51\">",
"      Carroccio A, Olin JW, Ellozy SH, et al. The role of aortic stent grafting in the treatment of atheromatous embolization syndrome: results after a mean of 15 months follow-up. J Vasc Surg 2004; 40:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/52\">",
"      Donas KP, Sch&ouml;nefeld T, Schwindt A, et al. Successful percutaneous endovascular treatment of symptomatic infrarenal aortic stenosis caused by soft-plaque with the Endurant stent-graft. J Cardiovasc Surg (Torino) 2011; 52:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/53\">",
"      Tsuji Y, Tanaka Y, Kitagawa A, et al. Endovascular stent-graft repair for penetrating atherosclerotic ulcer in the infrarenal abdominal aorta. J Vasc Surg 2003; 38:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10809/abstract/54\">",
"      Wolf PS, Burman HE, Starnes BW. Endovascular treatment of massive thoracic aortic thrombus and associated ruptured atheroma. Ann Vasc Surg 2010; 24:416.e9.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8197 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-103.10.120.51-1F944A4537-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_35_10809=[""].join("\n");
var outline_f10_35_10809=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H536302420\">",
"      THROMBOEMBOLISM VERSUS ATHEROEMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMPLEX AORTIC PLAQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Association with embolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk factors for embolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Plaque thickness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Plaque ulceration and mobility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Plaque location",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cardiovascular procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DETECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other imaging techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89902933\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89901660\">",
"      - Antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Lipid-lowering therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89902724\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89901908\">",
"      - Endovascular surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105343967\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8197\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8197|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/39/21104\" title=\"diagnostic image 1\">",
"      Thoracic aortic plaque",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8197|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/12/36045\" title=\"figure 1\">",
"      Stroke and severe aortic plaque",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8197|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?18/15/18686\" title=\"movie 1\">",
"      TEE aortic plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?4/35/4671\" title=\"movie 2\">",
"      TEE aortic arch",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=related_link\">",
"      Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=related_link\">",
"      Acute mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=related_link\">",
"      Cryptogenic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3834?source=related_link\">",
"      Neurologic complications of cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2168?source=related_link\">",
"      Prevention of neurologic complications of cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=related_link\">",
"      Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_35_10810="Systemic lupus erythematosus in children";
var content_f10_35_10810=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic lupus erythematosus in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/35/10810/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/35/10810/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/35/10810/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/35/10810/contributors\">",
"     Marisa Klein-Gitelman, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/35/10810/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/35/10810/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/35/10810/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic lupus erythematosus (SLE) in children is fundamentally the same disease as in adults with similar etiology, pathogenesis, clinical manifestations, and laboratory findings. However, the care of children and adolescents with SLE is very different from that of adults because of the impact of the disease and its therapy on physical and psychological growth and development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Failure of therapy of childhood SLE frequently results from efforts to care for a child or adolescent with a complex and chronic disease without considering the special needs of the growing individual and his or her family. As a result, clinicians who are unprepared to deal with these needs should refer these patients to a pediatric rheumatology center.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current best estimate is that SLE affects between 5000 and 10,000 children in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/1\">",
"     1",
"    </a>",
"    ]. Childhood SLE affects girls more often than boys (8:1), even in the prepubescent age group (4:1). Although it can occur at any age, SLE becomes more frequent after five years of age and is increasingly prevalent after the first decade of life [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=see_link&amp;anchor=H1#H1\">",
"     \"Epidemiology and pathogenesis of systemic lupus erythematosus\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because the incidence and severity of childhood SLE vary by race, a comparison of data from institutions serving racially diverse populations is generally unrevealing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients of Asian, African, or Latino ethnicity are all more frequently affected than Caucasians. Estimates of disease incidence between the ages of 10 and 18 in the United States among females of different ethnic groups are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      31 cases per 100,000 female Asians",
"     </li>",
"     <li>",
"      20 cases per 100,000 blacks",
"     </li>",
"     <li>",
"      13 cases per 100,000 Hispanics",
"     </li>",
"     <li>",
"      4 cases per 100,000 whites",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of SLE among black African children is not known, but the author&rsquo;s personal observation is that SLE is not infrequent among black children at the Baragwaneth Hospital in Soweto, South Africa. The estimate prevalence in Asia varies from 6 cases per 100,000 in Taiwan to 19 cases per 100,000 in central Saudi-Arabia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting manifestations of SLE in children are as diverse as they are in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/1\">",
"     1",
"    </a>",
"    ]. Although some children have acute or even life-threatening symptoms, the most common initial symptoms are the gradual onset of fever, malaise, and general deterioration over several months. Children also may have small joint arthritis and renal disease, both of which are commonly overlooked before the diagnosis of SLE is established. The classic malar rash is absent in two-thirds of individuals and must not be relied on to suggest the diagnosis (",
"    <a class=\"graphic graphic_picture graphicRef75781 \" href=\"UTD.htm?31/39/32371\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef55875 \" href=\"UTD.htm?3/47/3828\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In retrospective reviews from France, Canada, and the United Kingdom, the onset of juvenile SLE is at a median age of 12 to 13 years, with the disease developing in the majority of patients after eight years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In the French and Canadian studies, the most common presenting manifestations were as follows (",
"    <a class=\"graphic graphic_table graphicRef64565 \" href=\"UTD.htm?28/51/29500\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hematologic: anemia, lymphopenia, leukopenia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenia",
"     </li>",
"     <li>",
"      Mucocutaneous: malar rash",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      oral ulcers",
"     </li>",
"     <li>",
"      Musculoskeletal: arthritis or arthralgia",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Renal abnormalities (eg, nephritis and nephrotic syndrome)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These manifestations, in addition to seizures and lymphadenopathy, are more common in childhood-onset lupus than adult-onset lupus, whereas Raynaud phenomenon, pleuritis, and sicca are more common manifestations in adults at disease onset [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neurologic involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLE is often associated with a variety of neuropsychiatric manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/10-17\">",
"     10-17",
"    </a>",
"    ]. Headache is a frequent complaint. Adolescents commonly present with progressive deterioration in academic performance, withdrawal, depression, and social isolation. Often these findings initially are thought to represent teenage adjustment problems. SLE is only suspected when a full physical assessment and appropriate laboratory testing are performed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/18\">",
"     18",
"    </a>",
"    ]. More dramatic neurologic presentations of SLE include seizures, chorea, stroke, dementia, and coma. These may be accompanied by cranial neuropathies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    evidence of cerebritis.",
"   </p>",
"   <p>",
"    Antiribosomal P antibodies are associated with active disease, particularly neuropsychiatric, renal, or hepatic involvement, and are found more frequently in children than adults [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal involvement in SLE may vary from the detection of hematuria and proteinuria on routine examination to the presence of nephrotic syndrome or acute renal failure. Some degree of renal involvement is present in two-thirds of children with SLE evaluated at major medical centers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19290?source=see_link\">",
"     \"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lupus nephritis was identified in 37 percent of children with SLE enrolled in Medicaid from 2000 to 2004 in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/21\">",
"     21",
"    </a>",
"    ]. Diffuse proliferative (class IV) lupus nephritis occurs in about 20 percent of all children presenting for evaluation in whom a renal biopsy is performed, independent of the presence or absence of active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/22\">",
"     22",
"    </a>",
"    ]. This likely represents an over estimate of the actual incidence of renal disease, since the incidence is probably lower in children without clinical evidence of renal disease who are not biopsied. However, mild lupus nephritis is relatively common in some populations. In addition, patients who received glucocorticoid therapy prior to evaluation and diagnosis of SLE may have unreliable urine studies and should be biopsied to evaluate for lupus nephritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=see_link\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The respiratory system is involved in up to 77 percent of patients. The most common manifestations are pleural disease and a restrictive pattern with pulmonary function testing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/1\">",
"     1",
"    </a>",
"    ]. Children may also present with clinically silent but significant manifestations that are uncovered on formal pulmonary function tests (PFTs) with diffusing capacity for carbon monoxide (DLCO) studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/23\">",
"     23",
"    </a>",
"    ]. PFTs with DLCO should be performed periodically and whenever there are new or increasing complaints of shortness of breath. Children rarely present with predominant pulmonary manifestations, but pulmonary hemorrhage may be an abrupt and life-threatening event. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/34/42534?source=see_link\">",
"     \"Pulmonary manifestations of systemic lupus erythematosus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hematologic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematologic manifestations of SLE at presentation in children and adolescents include thrombocytopenia, hemolytic anemia, and persistent leukopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/24\">",
"     24",
"    </a>",
"    ]. The presence of any of these findings should prompt testing for antinuclear antibodies (ANA), once leukemia and other hematologic malignancies have been excluded. If an elevated ANA titer is found, the patients should be carefully evaluated for other manifestations of SLE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=see_link\">",
"     \"Measurement and clinical significance of antinuclear antibodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27303?source=see_link\">",
"     \"Hematologic problems in children and adolescents with systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with childhood SLE also may have antiphospholipid antibodies (aPL) or positive tests for lupus anticoagulant (LA) activity, which are associated with menorrhagia, prolonged clotting times, unexplained thrombosis, and stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/25\">",
"     25",
"    </a>",
"    ]. At times, a high titer aPL may be the only manifestation of SLE in a child with a positive ANA. Children and adolescents with SLE who have either aPL or LA should be presumed to have the same increased risk of developing a clotting disorder as adults with aPL [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/25-27\">",
"     25-27",
"    </a>",
"    ], and they should be treated accordingly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antineutrophil cytoplasmic antibodies (ANCA) also have been observed in SLE; however, their presence does not appear to be associated with disease activity or specific organ involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cardiac abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericarditis is the most common cardiac abnormality in children with SLE, but other problems such as myocarditis, valvular disease (eg, endocarditis), and coronary artery disease can occur. Cardiac abnormalities in children with SLE are often silent. Cardiac abnormalities in children with SLE are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31943?source=see_link\">",
"     \"Cardiac abnormalities in children and adolescents with systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other organ system involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;As observed in adults, every organ system may be involved by childhood SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/1,28\">",
"     1,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21435337\">",
"    <span class=\"h3\">",
"     Gastrointestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one case series of 201 children with SLE, 39 (19 percent) had gastrointestinal (GI) involvement. Symptoms included pain due to ascites (n = 14) or pancreatitis (n = 12), as well as GI symptoms resulting from complications of treatment (n = 1) or infection (n = 1) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/29\">",
"     29",
"    </a>",
"    ]. Pancreatitis in particular has increased morbidity. Mild hepatitis is a frequent finding at disease onset and resolves with initial treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5928?source=see_link\">",
"     \"Gastrointestinal manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21435344\">",
"    <span class=\"h3\">",
"     Bone abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one case series of 64 consecutive children with SLE, dual x-ray absorptiometry scanning demonstrated lumbar spine osteopenia in 24 patients (38 percent), osteoporosis in 13 (20 percent), and decreased hip bone mineral density (BMD) in 12 patients (19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/30\">",
"     30",
"    </a>",
"    ]. These findings are in large part due to glucocorticoid toxicity, which contributes to osteopenia and osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23753?source=see_link\">",
"     \"Musculoskeletal manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin D deficiency has been reported in children and adolescents with SLE, and may contribute to decreased bone density and osteopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/31\">",
"     31",
"    </a>",
"    ]. Hypovitaminosis D, which is also seen in adults with SLE, is thought to be due to avoidance of sun exposure. One study found an inverse correlation between serum concentrations of vitamin D and standardized disease activity scores, suggesting that hypovitaminosis D might have contributed to the development of active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/32\">",
"     32",
"    </a>",
"    ]. However, an earlier study did not identify such a correlation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/33\">",
"     33",
"    </a>",
"    ]. There are no currently available data on the effects of vitamin D supplementation on skeletal manifestations or disease activity in children with SLE. Until further data are available, children with SLE can be supplemented with an age-appropriate daily multivitamin to minimize the risk of hypovitaminosis D and other vitamin deficiencies. However, higher doses are not warranted based upon available data unless deficiency of vitamin D has been documented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"external\" href=\"file://onlinelibrary.wiley.com/doi/10.1002/art.34473/pdf\">",
"     Systemic Lupus International Collaborating Clinics (SLICC) group classification criteria",
"    </a>",
"    for SLE is a revised and validated version of the American College of Rheumatology (ACR) criteria used for adults (",
"    <a class=\"graphic graphic_table graphicRef86633 \" href=\"UTD.htm?1/31/1535\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. These same criteria are also used to classify children. A patient is classified as having SLE if four or more of the SLICC criteria, including at least one clinical and one immunologic criterion, are present either serially or simultaneously, during any interval of observations, in the absence of another explanation for the findings. An alternative requirement is positive antinuclear antibodies or anti-double-stranded DNA antibodies in conjunction with biopsy-proven lupus nephritis. Other factors, such as family history, age, duration of symptoms and evolution of findings, must be taken into account before classifying a child as having SLE, since none of the clinical or immunologic criteria for the classification of SLE are disease-specific. Some patients may have severe organ manifestations of lupus without fulfilling classification criteria and must be treated urgently or emergently without waiting for other criteria to develop. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A low index of suspicion for SLE in childhood is the primary impediment to a proper diagnosis. Delayed diagnosis may be due to the frequent absence of the typical findings of SLE at disease onset (eg, malar rash) or may be due to the high frequency of nonspecific complaints (such as weight loss, chronic low-grade fever, or malaise) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/1\">",
"     1",
"    </a>",
"    ]. There will be many children who do not initially reach sufficient criteria for classification as SLE, but who present with two or three manifestations. These children should be monitored over time for the development of additional criteria of SLE. There are examples of children who initially did not meet the definite criteria and were assured that they \"did not have SLE.\" In these cases, this false assurance led to a marked delay in return to medical care despite worsening symptoms.",
"   </p>",
"   <p>",
"    A single manifestation of SLE, such as thrombocytopenia, may predominate early in the course of the disease. Such children should be carefully evaluated for the presence of additional manifestations of SLE, including an elevated ANA titer. Repeated evaluation is necessary, as children who initially fulfill less than four of the ACR criteria may progress over time to definitive SLE. Such progression may occur over a period of three to five years or longer, and is typically accompanied by the gradual accrual of additional pathologic autoantibodies (eg, anti-Sm and anti-Ro) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less frequently, some children with SLE present acutely with a fever, rash, leukopenia, and thrombocytopenia, findings that are suggestive of overwhelming infection. Even among those with preexisting SLE, the differentiation of a disease flare from intercurrent sepsis may be difficult, and may require simultaneous treatment for both conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment for most manifestations of SLE does not differ among adults, children, and adolescents. However, children and adolescents with SLE have unique problems related to growth and development that affect both the need for and the impact of aggressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. The profound negative effects of glucocorticoids during physical and psychological growth and development necessitate minimizing the dose whenever possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The agent that best combines safety and efficacy for the treatment of SLE is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40965?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    . A review of 95 studies examining the effects of antimalarials on SLE found strong evidence of a beneficial effect on disease activity and survival, and convincing, though weaker, evidence of improvements in irreversible organ damage, thromboses, atherosclerosis, bone mineral density, and lipid profile [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/40\">",
"     40",
"    </a>",
"    ]. Adverse events from antimalarials were uncommon and tended to mild, although in rare cases use was associated with irreversible retinal toxicity. However, this agent works slowly and should not be expected to remedy more significant disease manifestations in a timely manner. Thus, it is best used as an addition to other agents rather than alone.",
"   </p>",
"   <p>",
"    There is general agreement among adult and pediatric rheumatologists that all patients with SLE should receive",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40965?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    during the entire course of the disease, including during pregnancy. In order to minimize the risk of irreversible visual damage, the hydroxychloroquine dose in children should be &le;7",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    and these children should have regular ophthalmic evaluations, including color vision and visual field testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians caring for children with SLE must remember that normal laboratory values for children differ from those for adults. As an example, a \"normal\" serum creatinine concentration in a child younger than 10 years of age is 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44",
"    <span class=\"nowrap\">",
"     micromol/L);",
"    </span>",
"    as a result, a level of 1.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (97",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    while \"normal\" in an adult, represents substantial renal failure in a young child. In addition, levels of compromised renal function that may have no clear adverse effect among adults may be inadequate to sustain normal growth and development in a child or adolescent.",
"   </p>",
"   <p>",
"    The emotional impact of SLE and its treatment also makes the care of children and adolescents distinct. Adolescence is a period of substantial psychologic stress associated with evolving self-identity. It is very difficult for these children to internalize the concept of chronic illness. The resultant sense of being different is markedly intensified by changes in their appearance, whether directly caused by the illness or as a result of therapy (eg, with glucocorticoids). Failure to deal appropriately with these issues often leads to noncompliance and a poor outcome.",
"   </p>",
"   <p>",
"    In particular, high-dose glucocorticoids have a profound impact on growth and appearance in children and adolescents. This impact is often associated with both physical impairment (ie, short stature",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    osteonecrosis) and psychological devastation. For many adolescents with SLE, their current Cushingoid appearance is of greater significance than any potential future event. Thus, both overt and covert suicide attempts (eg, surreptitious refusal to take necessary medications) are well recognized in centers caring for large numbers of adolescents. The treating clinician must do everything possible to minimize glucocorticoid toxicity and maximize compliance with the treatment regimen (including the use of other immunosuppressive agents as described below). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link&amp;anchor=H11#H11\">",
"     \"Causes of short stature\", section on 'Glucocorticoid therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mild SLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conservative care is indicated for the child with mild SLE who does not have renal or other life-threatening organ system involvement. The use of nonsteroidal antiinflammatory drugs (to control musculoskeletal manifestations) and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40965?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (&le;7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day up to 200 mg in most children with an adult maximum of 400 mg per day) may be sufficient in this setting. Patients on hydroxychloroquine must have regular ophthalmologic screening.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/31/34288?source=see_link\">",
"     Dapsone",
"    </a>",
"    may be helpful for the occasional child with primarily dermatologic manifestations. However, low-dose glucocorticoids (less than 0.35",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    ) are often necessary to attain adequate disease control. Long-term use of even such low amounts should be avoided if possible, however, as doses above 0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day may adversely affect longitudinal growth [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/41\">",
"     41",
"    </a>",
"    ]. Second line agents should be considered whether or not renal disease is present if glucocorticoids in a dosage of greater than 0.35",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    are required.",
"   </p>",
"   <p>",
"    Children with mild disease are increasingly common in large centers as more pediatricians identify such patients through appropriate screening for SLE. They should be followed closely however, as apparently mild cases may progress in severity over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Moderate SLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents with moderate SLE (eg, clinically significant, but not life-threatening, involvement of the kidneys or other vital organs) often require the continued use of high-dose glucocorticoids to control disease activity. Many centers attempt to manage glucocorticoid toxicity by using higher dose alternate day oral therapy or intermittent intravenous (IV) high dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    . However, a much higher oral dose is often required on the alternate days. Intravenous high dose methylprednisolone has the advantage of shutting down the lupus interferon signature, an effect that is not seen with oral glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some centers use",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    as steroid-sparing agents in these children, because of the concerns noted above about glucocorticoid toxicity. There is extensive experience with azathioprine and increasing experience with mycophenolate mofetil [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/43\">",
"     43",
"    </a>",
"    ], although reports of the usefulness of methotrexate in SLE are less conclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/44\">",
"     44",
"    </a>",
"    ]. One study of the use of methotrexate evaluated 10 children in whom further therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    with or without",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    was precluded [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/45\">",
"     45",
"    </a>",
"    ]. Eight showed marked improvement with low-dose (5 to 10 mg per week) methotrexate; these patients were able to taper prednisone and to discontinue cyclophosphamide. However, most centers find a lower incidence of success with methotrexate in SLE. At the Hospital for Special Surgery, children whose disease does not quickly come under control with these regimens often are advanced to intravenous cyclophosphamide. The use of methotrexate in children with renal disease must be carefully monitored, since methotrexate is excreted in the urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Severe SLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents with severe SLE (eg, substantial renal or neurologic disease) require more aggressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/46\">",
"     46",
"    </a>",
"    ]. As in adults, children with the diffuse proliferative type of lupus nephritis have the worst prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=see_link\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    appears to have the best-documented long-term success rate in children and adults with severe SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/48-50\">",
"     48-50",
"    </a>",
"    ], despite scattered studies suggesting comparable outcomes with agents such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/51\">",
"     51",
"    </a>",
"    ]. The regimen we prefer is based upon the National Institute of Health protocol developed during the 1980s and 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/52\">",
"     52",
"    </a>",
"    ]. It consists of monthly intravenous pulses of cyclophosphamide (500",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    increasing to 1",
"    <span class=\"nowrap\">",
"     g/m2",
"    </span>",
"    as tolerated) for six months, followed by every three months cyclophosphamide for an additional 30 months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    regimen has been very successful in the treatment of children with diffuse proliferative glomerulonephritis. In one study, intravenous cyclophosphamide was given to eight children with steroid-unresponsive lupus nephritis and eight with either steroid-dependent nephrosis or active lupus nephritis and unacceptable steroid-induced side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/48\">",
"     48",
"    </a>",
"    ]. Cyclophosphamide therapy significantly reduced proteinuria (1.0 versus 3.2 g per day, p&lt;0.05) and increased creatinine clearance among those with decreased function prior to therapy (121 versus 57.5",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, p&lt;0.05). We also have documented that this program of cyclophosphamide administration prevents progression of renal scarring in a study of 16 children with renal biopsies performed before and following three years of cyclophosphamide therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a variety of rheumatologic conditions,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    increasingly is being used as an induction agent. This involves a seven-infusion course of monthly pulsed doses followed by conversion to a less toxic maintenance medication such as mofetil",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    . In adult studies of vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/53\">",
"     53",
"    </a>",
"    ] and SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/54\">",
"     54",
"    </a>",
"    ], this has appeared to optimize benefits of the more potent drug while minimizing exposure and long-term toxicity. An absence of data precludes favoring one approach over another.",
"   </p>",
"   <p>",
"    The use of intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    was initially restricted to children with life-threatening diffuse proliferative glomerulonephritis. With extensive use, however, we have found that this regimen permits a reduction in daily glucocorticoid use to a minimal level and is associated with acceptable long-term safety [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/49\">",
"     49",
"    </a>",
"    ]. Therefore, we have broadened its use to all children with moderate or severe SLE who cannot be maintained on an acceptable level of glucocorticoids and other glucocorticoid-sparing agents. Specifically, we use intravenous cyclophosphamide in children who cannot otherwise be maintained on a",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    dose of less than 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day despite use of steroid-sparing agents.",
"   </p>",
"   <p>",
"    Many centers use",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil instead of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , particularly where there is significant risk to future gonadal function and there is no data to support a specific steroid-sparing agent. However, mycophenolate mofetil is associated with a significant incidence of stomach upset and requires consistent twice or three times daily dosing to be effective. As a result, compliance can become problematic, particularly in adolescents. GI side effects are reduced with an enteric coated formulation. While cyclophosphamide may be no more effective in controlled studies, it is much easier to ascertain compliance with a monthly intravenous medication than with a daily oral medication.",
"   </p>",
"   <p>",
"    The need for extended immunosuppressive therapy varies based upon organ involvement. In children with nephritis, for example, there is an unacceptable frequency of disease flare when",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is discontinued after the initial seven doses without substitution with an alternative immunosuppressive agent. In contrast, a one-year course may be sufficient for those with extrarenal disease only.",
"   </p>",
"   <p>",
"    The long-term safety of intravenous pulse",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in children is not well defined. With respect to gonadal toxicity, data from oral therapy suggest that the risk is greatest in sexually mature males and lowest in prepubertal children; girls rarely become infertile. The clinician should consider sperm banking or ovarian protection to reduce the risk of infertility when cyclophosphamide is needed if the family is concerned, but the author has many female patients who have successfully begun families following completion of intravenous cyclophosphamide therapy without taking any specific protective measures during therapy. With the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/22/44388?source=see_link\">",
"     MESNA",
"    </a>",
"    the risk of bladder toxicity is markedly reduced, but the effect on other toxicities is not yet known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some children develop recurrent disease following withdrawal of intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy. There is no consensus on how to treat such patients. Options include a multi-drug regimen consisting of intravenous cyclophosphamide and intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    monthly for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/55\">",
"     55",
"    </a>",
"    ], one to two doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    with or without cyclophosphamide, and other biologic or immunosuppressive agents. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Other therapeutic options'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Other therapeutic options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other therapeutic options include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      &mdash; Children with renal disease resistant to other immunosuppressive agents may benefit from treatment with mycophenolate mofetil [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/43,56,57\">",
"       43,56,57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one study of 11 children with lupus nephritis, all four with membranous lupus improved on",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , although those with proliferative nephritis had little renal benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/43\">",
"       43",
"      </a>",
"      ]. Disease activity was reduced in 10 of the children and mean glucocorticoid dose was decreased in six. Adverse effects were common (infection, leukopenia, nausea, pruritus, headache, and fatigue).",
"     </li>",
"     <li>",
"      In another study, 16 children with severe proliferative lupus nephritis were treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/56\">",
"       56",
"      </a>",
"      ]. Thirteen patients were also treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      . Significant improvement was seen in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), proteinuria, and serologic markers (C3, C4, and anti-dsDNA). Complete remission was attained by 44 and 75 percent at 6 and 12 months, respectively. The remaining patients achieved partial remission. The most common side effect reported was infection. No serious adverse effects were noted.",
"     </li>",
"     <li>",
"      Adherence to the twice-daily dosing of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      is sometimes a challenge compared with monthly IV",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , particularly when the patient also develops abdominal pain or diarrhea. Patients often do better with the enteric coated form of the drug. Many patients are willing to make an effort to take the oral medication, especially in view of its lack of association with infertility or carcinogenesis, although clinical experience demonstrates a significant risk of medication nonadherence. Mycophenolate levels can be monitored and some patients may need alteration of usual dosing due to personal pharmacokinetics and pharmacogenetics. A short pharmacokinetic study can be performed in the clinic to assess this.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"       Rituximab",
"      </a>",
"      &mdash; In several uncontrolled retrospective studies, rituximab (Rituxan&reg;), a chimeric anti-CD20 monoclonal antibody, has been used effectively, often in combination with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , in the treatment of children with severe SLE refractory to conventional therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/58-60\">",
"       58-60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the largest of these studies, 19 children (median age 14 years) were treated with two doses of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"       rituximab",
"      </a>",
"      (750",
"      <span class=\"nowrap\">",
"       mg/m2)",
"      </span>",
"      given two weeks apart [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/60\">",
"       60",
"      </a>",
"      ]. Patients also received oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"       prednisolone",
"      </a>",
"      , and 12 patients were treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      . All patients had improvement in their clinical symptoms with reduction of SLE disease activity assessed by the British Isle Lupus Assessment Group (BILAG) index and by laboratory evaluation (hematologic parameters, complement levels, erythrocyte sedimentation rate, serum creatinine and albumin, and urine",
"      <span class=\"nowrap\">",
"       protein/creatinine",
"      </span>",
"      ratio). No serious adverse effects were noted except for herpes zoster in five cases.",
"     </li>",
"     <li>",
"      In another study,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"       rituximab",
"      </a>",
"      was given to 11 patients with a wide variation in dosing regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/59\">",
"       59",
"      </a>",
"      ]. Patients received 2 to 12 infusions of rituximab with doses that ranged from 350 to 450",
"      <span class=\"nowrap\">",
"       mg/m2.",
"      </span>",
"      Patients also received glucocorticoids. Eight of the 11 patients had complete or partial remission of their disease. However, five patients had severe adverse effects including septicemia, thrombocytopenia, and neutropenia. These complications are difficult to interpret given the diversity of the clinical presentations and the treatment regimens used.",
"     </li>",
"     <li>",
"      In a combined open trial of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"       rituximab",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , the concurrent use of both of these agents allowed shortening of the previously used cyclophosphamide regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/61\">",
"       61",
"      </a>",
"      ]. Patients had both improved clinical responses and decreased drug-related toxicity.",
"     </li>",
"     <li>",
"      Uncontrolled studies and anecdotal reports appear to support",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"       rituximab",
"      </a>",
"      as an effective therapy for the treatment of SLE [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/62\">",
"       62",
"      </a>",
"      ]. However, controlled clinical trials in adults have failed to confirm such efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/63\">",
"       63",
"      </a>",
"      ]. Caution is particularly warranted in view of the rare reports of severe, and often fatal, complications in some adults treated with rituximab [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/64\">",
"       64",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link&amp;anchor=H334601#H334601\">",
"       \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\", section on 'Rituximab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematopoietic cell transplantation &mdash; Some have advocated autologous hematopoietic cell transplantation (HCT) for children with severe SLE [",
"      <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/65,66\">",
"       65,66",
"      </a>",
"      ]. In our hands, \"conventional\" therapy has proven adequate. Thus, the use of HCT is likely to remain largely theoretical, until the morbidity and mortality of this intervention can be reduced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Efficacy of different therapeutic regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to compare the long-term results of differing regimens used at various centers. Much of the problem results from racial and socioeconomic disparities in the populations served, as well as subtle but potentially important differences between therapeutic protocols. These differences are compounded by the frequent failure to adequately describe the condition of children being entered in various protocols.",
"   </p>",
"   <p>",
"    Within pediatric rheumatology, the routine use of staging criteria is gaining increased acceptance as a tool to assess efficacy of different therapeutic regimens in juvenile SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/67\">",
"     67",
"    </a>",
"    ]. The Pediatric Rheumatology International Trials Organization (PRINTO) has developed and validated a set of criteria to measure clinical response to therapy in children with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/68\">",
"     68",
"    </a>",
"    ]. These criteria are similar to those used in patients with juvenile idiopathic arthritis. They include questionnaire-based assessments by the clinician, patient, and parents on disease activity, patient well-being and quality of life, as well as clinical assessment of the patient using a global disease activity index (eg, European Consensus Lupus Activity Measurement, ECLAM). Global disease activity indices utilize a combination of history, examination, and laboratory data. These indices were designed to monitor response to therapy in adults with SLE, however none have been universally adopted. They are hampered by the enormous variability of disease manifestations in different cases of lupus, rendering meaningful comparison difficult. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\", section on 'Disease activity indices'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Continued efforts are needed to establish a universally accepted set of criteria for assessment of response to therapy in juvenile SLE. A practical and accurate set of staging criteria will substantially improve our ability to compare the effects of different therapeutic regimens in children with SLE. This work is ongoing and consensus to define lupus disease flare, remission, and response to therapy are forthcoming [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of children and adolescents with SLE who receive appropriate care is generally very good. The primary causes of an unsatisfactory outcome are [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/47,71\">",
"     47,71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor compliance secondary to poor patient and family education",
"     </li>",
"     <li>",
"      Neurologic complications",
"     </li>",
"     <li>",
"      Intercurrent infections",
"     </li>",
"     <li>",
"      Renal disease, especially diffuse proliferative glomerulonephritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of atypical manifestations (eg, clinical features previously reported as associated with SLE, but not included in the classification criteria) at disease onset is also associated with greater cumulative organ damage [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of 35 patients followed for a median of 2.8 years (range 0.7 to 14.3 years), the following disease activity patterns were seen: chronic active (49 percent), relapse remitting (14 percent), and long quiescence (37 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/72\">",
"     72",
"    </a>",
"    ]. Chronic active disease was associated with positive anti-Sm. Early aggressive treatment in patients with severe symptoms was associated with a more favorable disease course.",
"   </p>",
"   <p>",
"    The overall survival rate for children and adolescents with SLE receiving current treatment approaches is unknown. Published data from the early 1980s documented survival rates of nearly 100 percent at 5 years and 85 percent at 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. In children as well as adults, increased mortality rates are associated with lower socioeconomic status of the family, increased disease activity, and central nervous system (CNS) or renal involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of renal involvement will affect the mortality and morbidity of children with SLE. This was illustrated in a retrospective study of 66 Canadian children, all of whom had renal-biopsy documented disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/75\">",
"     75",
"    </a>",
"    ]. The results are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with diffuse proliferative disease, (WHO Class IV) all of whom received glucocorticoids, and the majority either",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/10/2216?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , the 10- and 19-year mortality rates were 9 and 12 percent, respectively. End-stage renal disease had developed in approximately 25 and 40 percent, respectively, by the same time points. Caucasian children fared better than others; 14 of 16 such children (87 percent) were alive without end-stage renal disease at the last follow up visit, versus 9 of 16 (56 percent) of non-Caucasian patients.",
"     </li>",
"     <li>",
"      For patients with mesangial (15 patients) or focal proliferative (8 patients) nephritis, there were no deaths and no child with these types (WHO Class II and III) developed end-stage renal disease at follow-up of up to 21 years (mean 11 years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results also highlight the importance of carefully assessing the ethnic characteristics of the population when comparing clinical outcome by varying institutions. Non-Caucasian children, particularly those of African-American ethnicity, have a poorer clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/76\">",
"     76",
"    </a>",
"    ]. Thus, the relatively higher percentage of Caucasian children in this Canadian study must be considered when comparing these results with those of American centers.",
"   </p>",
"   <p>",
"    When treatment fails to prevent progression of renal disease, children with kidney failure resulting from lupus nephritis appear to do as well after renal transplantation as do children with other causes of end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40680?source=see_link\">",
"     \"Outcomes of renal transplantation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Long-term outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our obligation in caring for a child or adolescent with SLE extends beyond the narrow view of providing adequate 5- or 10-year survival rates. For a 15-year-old, for example, surviving for this period of time means to live to an age of only 20 or 25 years. We must therefore seek optimal 50-year survivals if our adolescent patients are to achieve a normal life span. For this to be accomplished, we need to minimize not only the morbidity of the disease, but also the adverse effects of the medications we are using to treat the disease.",
"   </p>",
"   <p>",
"    At present, it is too early to assess the 15-year survival rate for adolescents treated with systematic intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    pulses. However, the experience of the last 10 years has taught us that this regimen is associated with a profound improvement in the quality of life with a dramatic reduction in total glucocorticoid dose and related complications, decreased school absence, decreased infections, and decreased emergency hospitalizations. In addition, further work is needed to ensure improved survival for non-Caucasian children that is equivalent to that achieved by Caucasian patients.",
"   </p>",
"   <p>",
"    In adults with SLE, long-term cardiovascular disease (CVD) is a major cause of death. Cardiac disease in children with SLE is often silent and, therefore, may be underestimated. In addition, children with SLE are at increased risk for early atherosclerosis and coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/35/10810/abstract/78\">",
"     78",
"    </a>",
"    ]. Continued endeavors to identify the prevalence and risk factors of cardiac disease in children with SLE are needed and ultimately will aid in improving long-term survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31943?source=see_link\">",
"     \"Cardiac abnormalities in children and adolescents with systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23122429\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic lupus erythematosus (SLE) in children is fundamentally the same disease as in adults with similar etiology, pathogenesis, clinical manifestations, and laboratory findings. However, the care of children and adolescents with SLE differs from that of adults because of the impact of the disease and its therapy on physical and psychological growth and development. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=see_link\">",
"       \"Overview of the clinical manifestations of systemic lupus erythematosus in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The incidence and severity of childhood SLE vary by race. Asians, Blacks, and Hispanics are all more frequently affected than Caucasians. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common initial symptoms are the gradual onset of fever, malaise, and general deterioration over several months. Children also may have small joint arthritis and renal disease, both of which are commonly overlooked before the diagnosis of SLE is established. The classic malar rash is absent in two-thirds of individuals and must not be relied on to suggest the diagnosis. Hematologic, neuropsychiatric, and pulmonary manifestations are also common. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://onlinelibrary.wiley.com/doi/10.1002/art.34473/pdf\">",
"       Systemic Lupus International Collaborating Clinics (SLICC) group classification criteria",
"      </a>",
"      are used to diagnose SLE in both children and adults. A patient is classified as having SLE if four or more of the SLICC criteria, including at least one clinical and one immunologic criterion, are present either serially or simultaneously, during any interval of observations, in the absence of another explanation for the findings. An alternative requirement is positive antinuclear antibodies or anti-double-stranded DNA antibodies in conjunction with biopsy-proven lupus nephritis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link&amp;anchor=H8#H8\">",
"       \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\", section on 'Diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The treatment for most manifestations of SLE does not differ among adults, children, and adolescents. However, children and adolescents with SLE have unique problems related to growth and development that affect both the need for and the impact of aggressive therapy. The profound negative effects of glucocorticoids during physical and psychological growth and development necessitate minimizing the dose whenever possible. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest treating all children with SLE with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40965?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      at a dose &le;7",
"      <span class=\"nowrap\">",
"       mg/kg/day.",
"      </span>",
"     </li>",
"     <li>",
"      The use of nonsteroidal antiinflammatory drugs (to control musculoskeletal manifestations) in conjunction with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40965?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      (7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day up to a usual maximum of 400 mg per day) is often sufficient in the child with mild SLE who does not have a significant requirement for glucocorticoids, renal or other life-threatening organ system involvement and poor compliance. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Mild SLE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children and adolescents with moderate SLE often require the continued use of high-dose glucocorticoids to control disease activity. Most centers use",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, or other steroid-sparing agents in these children, because of the unacceptable toxicity associated with high dose glucocorticoids. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Moderate SLE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children and adolescents with severe SLE (eg, substantial renal or neurologic disease), or those with moderate disease that does not quickly come under control, require more aggressive therapy. Monthly intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      is generally preferred in children with moderate or severe SLE who cannot be maintained on a",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      dose of less than 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. Extended immunosuppressive therapy is often required for patients with renal disease, but a one-year course may be sufficient for those with extrarenal disease only. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Severe SLE'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The survival rate for children and adolescents with SLE is nearly 100 percent at 5 years and at least 85 percent at 10 years. Higher mortality rates are associated with lower socioeconomic status of the family, increased disease activity, and central nervous system (CNS) or renal involvement. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Lehman TJ. Systemic lupus erythematosus in children and adolescents. In: Dubois' Systemic Lupus Erythematosus, 5th ed, Wallace DA, Hahn B (Eds), WB Saunders, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/2\">",
"      Lehman TJ, McCurdy DK, Bernstein BH, et al. Systemic lupus erythematosus in the first decade of life. Pediatrics 1989; 83:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/3\">",
"      Huang JL, Yeh KW, Yao TC, et al. Pediatric lupus in Asia. Lupus 2010; 19:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/4\">",
"      Huang JL, Yao TC, See LC. Prevalence of pediatric systemic lupus erythematosus and juvenile chronic arthritis in a Chinese population: a nation-wide prospective population-based study in Taiwan. Clin Exp Rheumatol 2004; 22:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/5\">",
"      Al-Arfaj AS, Al-Balla SR, Al-Dalaan AN, et al. Prevalence of systemic lupus erythematosus in central Saudi Arabia. Saudi Med J 2002; 23:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/6\">",
"      Bader-Meunier B, Armengaud JB, Haddad E, et al. Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J Pediatr 2005; 146:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/7\">",
"      Hiraki LT, Benseler SM, Tyrrell PN, et al. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 2008; 152:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/8\">",
"      Watson L, Leone V, Pilkington C, et al. Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. Arthritis Rheum 2012; 64:2356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/9\">",
"      Livingston B, Bonner A, Pope J. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus 2011; 20:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/10\">",
"      Arkachaisri T, Lehman TJ. Systemic lupus erythematosus and related disorders of childhood. Curr Opin Rheumatol 1999; 11:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/11\">",
"      Yancey CL, Doughty RA, Athreya BH. Central nervous system involvement in childhood systemic lupus erythematosus. Arthritis Rheum 1981; 24:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/12\">",
"      Carbotte RM, Denburg SD, Denburg JA. Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis 1986; 174:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/13\">",
"      Papero PH, Bluestein HG, White P, Lipnick RN. Neuropsychologic deficits and antineuronal antibodies in pediatric systemic lupus erythematosus. Clin Exp Rheumatol 1990; 8:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/14\">",
"      Quintero-Del-Rio AI. Neurologic symptoms in children with systemic lupus erythematosus. J Child Neurol 2000; 15:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/15\">",
"      Benseler SM, Silverman ED. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus 2007; 16:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/16\">",
"      Sibbitt WL Jr, Brandt JR, Johnson CR, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002; 29:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/17\">",
"      Olfat MO, Al-Mayouf SM, Muzaffer MA. Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus. Clin Rheumatol 2004; 23:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/18\">",
"      Brunner HI, Ruth NM, German A, et al. Initial validation of the Pediatric Automated Neuropsychological Assessment Metrics for childhood-onset systemic lupus erythematosus. Arthritis Rheum 2007; 57:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/19\">",
"      Reichlin M, Broyles TF, Hubscher O, et al. Prevalence of autoantibodies to ribosomal P proteins in juvenile-onset systemic lupus erythematosus compared with the adult disease. Arthritis Rheum 1999; 42:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/20\">",
"      Kiss E, Shoenfeld Y. Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus? Clin Rev Allergy Immunol 2007; 32:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/21\">",
"      Hiraki LT, Feldman CH, Liu J, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum 2012; 64:2669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/22\">",
"      Malleson PN. The role of the renal biopsy in childhood onset systemic lupus erythematosus: a viewpoint. Clin Exp Rheumatol 1989; 7:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/23\">",
"      Al-Abbad AJ, Cabral DA, Sanatani S, et al. Echocardiography and pulmonary function testing in childhood onset systemic lupus erythematosus. Lupus 2001; 10:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/24\">",
"      McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/25\">",
"      Schmugge M, Revel-Vilk S, Hiraki L, et al. Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus. J Pediatr 2003; 143:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/26\">",
"      Seaman DE, Londino AV Jr, Kwoh CK, et al. Antiphospholipid antibodies in pediatric systemic lupus erythematosus. Pediatrics 1995; 96:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/27\">",
"      Descloux E, Durieu I, Cochat P, et al. Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies. Rheumatology (Oxford) 2008; 47:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/28\">",
"      Stichweh D, Arce E, Pascual V. Update on pediatric systemic lupus erythematosus. Curr Opin Rheumatol 2004; 16:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/29\">",
"      Richer O, Ulinski T, Lemelle I, et al. Abdominal manifestations in childhood-onset systemic lupus erythematosus. Ann Rheum Dis 2007; 66:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/30\">",
"      Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, et al. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum 2007; 56:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/31\">",
"      Wright TB, Shults J, Leonard MB, et al. Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus. J Pediatr 2009; 155:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/32\">",
"      Amital H, Szekanecz Z, Sz&uuml;cs G, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis 2010; 69:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/33\">",
"      Ruiz-Irastorza G, Egurbide MV, Olivares N, et al. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 2008; 47:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/34\">",
"      Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/35\">",
"      Petri M, Orbai AM, Alarc&oacute;n GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/36\">",
"      Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349:1526.",
"     </a>",
"    </li>",
"    <li>",
"     Lehman TJ. The clinical management of systemic lupus erythematosus in children and adolescents. In: The clinical management of systemic lupus erythematosus, 2nd ed, Schur PH (Ed), Lippincott-Raven, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/38\">",
"      Lehman TJ. Modern treatment of childhood SLE. Clin Exp Rheumatol 2001; 19:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/39\">",
"      Marks SD, Tullus K. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. Acta Paediatr 2010; 99:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/40\">",
"      Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/41\">",
"      David J, Loftus J, Hesp R, et al. Spinal and somatic growth in patients with juvenile chronic arthritis treated for up to 2 years with deflazacort. Clin Exp Rheumatol 1992; 10:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/42\">",
"      Guiducci C, Gong M, Xu Z, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010; 465:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/43\">",
"      Buratti S, Szer IS, Spencer CH, et al. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001; 28:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/44\">",
"      Ravelli A, Ballardini G, Viola S, et al. Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus. J Rheumatol 1998; 25:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/45\">",
"      Abud-Mendoza C, Sturbaum AK, Vazquez-Compean R, Gonzalez-Amaro R. Methotrexate therapy in childhood systemic lupus erythematosus. J Rheumatol 1993; 20:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/46\">",
"      Mina R, von Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/47\">",
"      McCurdy DK, Lehman TJ, Bernstein B, et al. Lupus nephritis: prognostic factors in children. Pediatrics 1992; 89:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/48\">",
"      Lehman TJ, Sherry DD, Wagner-Weiner L, et al. Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 1989; 114:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/49\">",
"      Lehman TJ. Long-term outcome of systemic lupus erythematosus in childhood. What is the prognosis? Rheum Dis Clin North Am 1991; 17:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/50\">",
"      Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000; 136:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/51\">",
"      Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/52\">",
"      Austin HA 3rd, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/53\">",
"      Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 51:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/54\">",
"      Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/55\">",
"      Lehman TJ, Edelheit BS, Onel KB. Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis. Ann Rheum Dis 2004; 63:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/56\">",
"      Aragon E, Chan YH, Ng KH, et al. Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus nephritis. Lupus 2010; 19:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/57\">",
"      Kazyra I, Pilkington C, Marks SD, Tullus K. Mycophenolate mofetil treatment in children and adolescents with lupus. Arch Dis Child 2010; 95:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/58\">",
"      Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005; 52:3168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/59\">",
"      Willems M, Haddad E, Niaudet P, et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006; 148:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/60\">",
"      Podolskaya A, Stadermann M, Pilkington C, et al. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child 2008; 93:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/61\">",
"      MacDermott EJ, Lehman TJ. Prospective, open-label trial of rituximab in childhood systemic lupus erythematosus. Curr Rheumatol Rep 2006; 8:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/62\">",
"      Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62:2458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/63\">",
"      Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/64\">",
"      Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/65\">",
"      Lisukov IA, Sizikova SA, Kulagin AD, et al. High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus. Lupus 2004; 13:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/66\">",
"      Milanetti F, Abinun M, Voltarelli JC, Burt RK. Autologous hematopoietic stem cell transplantation for childhood autoimmune disease. Pediatr Clin North Am 2010; 57:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/67\">",
"      Lehman TJ. A practical guide to systemic lupus erythematosus. Pediatr Clin North Am 1995; 42:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/68\">",
"      Ruperto N, Ravelli A, Cuttica R, et al. The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. Arthritis Rheum 2005; 52:2854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/69\">",
"      Brunner HI, Mina R, Pilkington C, et al. Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2011; 63:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/70\">",
"      Mina R, Klein-Gitelman MS, Ravelli A, et al. Inactive disease and remission in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/71\">",
"      Taddio A, Rossetto E, Ros&eacute; CD, et al. Prognostic impact of atypical presentation in pediatric systemic lupus erythematosus: results from a multicenter study. J Pediatr 2010; 156:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/72\">",
"      Otten MH, Cransberg K, van Rossum MA, et al. Disease activity patterns in juvenile systemic lupus erythematosus and its relation to early aggressive treatment. Lupus 2010; 19:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/73\">",
"      Platt JL, Burke BA, Fish AJ, et al. Systemic lupus erythematosus in the first two decades of life. Am J Kidney Dis 1982; 2:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/74\">",
"      Glidden RS, Mantzouranis EC, Borel Y. Systemic lupus erythematosus in childhood: clinical manifestations and improved survival in fifty-five patients. Clin Immunol Immunopathol 1983; 29:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/75\">",
"      Hagelberg S, Lee Y, Bargman J, et al. Longterm followup of childhood lupus nephritis. J Rheumatol 2002; 29:2635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/76\">",
"      Pereira T, Abitbol CL, Seeherunvong W, et al. Three decades of progress in treating childhood-onset lupus nephritis. Clin J Am Soc Nephrol 2011; 6:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/77\">",
"      Bartosh SM, Fine RN, Sullivan EK. Outcome after transplantation of young patients with systemic lupus erythematosus: a report of the North American pediatric renal transplant cooperative study. Transplantation 2001; 72:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/35/10810/abstract/78\">",
"      Spiera H, Rothenberg RR. Myocardial infarction in four young patients with SLE. J Rheumatol 1983; 10:464.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6420 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.202-C708E0D7D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_35_10810=[""].join("\n");
var outline_f10_35_10810=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23122429\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neurologic involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hematologic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cardiac abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other organ system involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21435337\">",
"      - Gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21435344\">",
"      - Bone abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mild SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Moderate SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Severe SLE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Other therapeutic options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Efficacy of different therapeutic regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Long-term outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23122429\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6420\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6420|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/39/32371\" title=\"picture 1\">",
"      Acute cutaneous lupus erythematosus - malar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/47/3828\" title=\"picture 2\">",
"      Acute cutaneous lupus erythematosus - malar eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6420|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/51/29500\" title=\"table 1\">",
"      SLE presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/31/1535\" title=\"table 2\">",
"      Classification criteria for SLE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19290?source=related_link\">",
"      Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31943?source=related_link\">",
"      Cardiac abnormalities in children and adolescents with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=related_link\">",
"      Epidemiology and pathogenesis of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5928?source=related_link\">",
"      Gastrointestinal manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27303?source=related_link\">",
"      Hematologic problems in children and adolescents with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23753?source=related_link\">",
"      Musculoskeletal manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40680?source=related_link\">",
"      Outcomes of renal transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=related_link\">",
"      Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/34/42534?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=related_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_35_10811="Risk factors for yersiniosis";
var content_f10_35_10811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors associated with development or severity of yersiniosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk Factor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Attributable risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consumption of undercooked or raw pork products",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exposure to untreated surface water",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minority infants (United States)",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood transfusion",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Derangements of iron-metabolism (cirrhosis, hemochromatosis, aplastic anemia, thalassemia, iron-overload)",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other conditions (malignancy, diabetes, malnutrition, gastrointestinal illness)",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_35_10811=[""].join("\n");
var outline_f10_35_10811=null;
var title_f10_35_10812="Pediatric airway equipment";
var content_f10_35_10812=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Airway equipment for pediatric patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Supplemental oxygen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasal cannulae (infant, child, and adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clear oxygen masks (standard and nonrebreathing - infant, child, and adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Suction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suction catheters (6 through 16 French)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yankauer suction tip (two sizes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bag-mask ventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Masks (neonate, infant, child, adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Self-inflating resuscitator bag (450 and 1000 mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Artificial airways",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oropharyngeal airways (sizes 0 through 5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasopharyngeal airways (12 through 30 French)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intubation equipment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endotracheal tubes (uncuffed and cuffed, 2.5 through 8.0 mm internal diameter)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stylets (infant, pediatric, and adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laryngoscope handle (pediatric and adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laryngoscope blades: straight (sizes 0, 1, 2, and 1.5 Wis-Hipple) and curved (sizes 2 and 3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Rescue airway devices",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laryngeal mask airway (sizes 1, 1.5, 2, 2.5, 3, 4, and 5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Combitube (37 and 41 French)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        End-tidal CO2 detector",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magill forceps (pediatric and adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bulb suction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_35_10812=[""].join("\n");
var outline_f10_35_10812=null;
var title_f10_35_10813="Monitoring type1 GD B";
var content_f10_35_10813=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mimimum recommended initial assessment and monitoring recommendations for patients with nonneuronopathic Gaucher disease - part 2*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Initial assessment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Not receiving ERT",
"       </td>",
"       <td class=\"subtitle2\">",
"        Receiving ERT, has not achieved goals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Cardiopulmonary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"3\">",
"        Children:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Forced vital capacity",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"5\">",
"        Repeat if abnormal at baseline or if symptoms develop",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"5\">",
"        Repeat if abnormal at baseline or if symptoms develop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Peak expiratory flow rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        High resolution chest radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Echochardiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Electrocardiogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"3\">",
"        Adults (&gt;18 years):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Electrocardiogram",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        <p>",
"         Every 12-24 months for those with borderline or above normal pulmonary pressures at baseline",
"        </p>",
"        <p>",
"         Consider repeating every 2-3 years if baseline is normal",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Chest radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Doppler echocardiogram (right ventricular systolic pressure)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Pain",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"       <td>",
"        Every 6-12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Quality of life",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Additional tests",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        White blood count, prothrombin time, activated partial thromboplastin time, iron, iron binding capacity, ferritin, vitamin B12, aspartate aminotransferase, and/or alanine aminotransferase; alkaline phosphatase; calcium, phosphorous, albumin, total protein, total and direct bilirubin; hepatitis profile, serum immunoelectrophoresis.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ERT: enzyme replacement therapy.",
"     <br>",
"      * The entire assessment should be performed every 12 to 24 months in patients who are receiving ERT and have achieved therapeutic goals (DEXA should be performed every 24 months in these patients); the entire assessment also should be performed at the time of dosage change or the development of a significant complication.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Additional tests to be considered and followed appropriately depending upon patient's age and clinical status.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Grabowski GA, Andria G, Baldellou A, et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 2004; 163:58.",
"       </li>",
"       <li>",
"        Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004; 163:67.",
"       </li>",
"       <li>",
"        Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004; 144:112.",
"       </li>",
"       <li>",
"        Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004; 41:15.",
"       </li>",
"       <li>",
"        Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 2005; 105:4569.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_35_10813=[""].join("\n");
var outline_f10_35_10813=null;
var title_f10_35_10814="Mortality ESRD pts 2007 USRDS";
var content_f10_35_10814=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F83658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F83658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    All-cause mortality among ESRD patients from 2007 USRDS data",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 385px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ESRD: prevalent ESRD patients, 2007. General Medicare: non-ESRD patients with at least one month of Medicare eligibility in 2007. Adjusted for gender and race. Medicare patients, 2007, used as reference cohort.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: U.S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009. The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_35_10814=[""].join("\n");
var outline_f10_35_10814=null;
var title_f10_35_10815="Gram stain CSF 5B with answer";
var content_f10_35_10815=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Listeria monocytogenes on blood agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The clear areas around each colony of Listeria monocytogenes are characteristic small zones of beta-hemolysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_35_10815=[""].join("\n");
var outline_f10_35_10815=null;
